

## Medical Policy

### Experimental and Investigational

**Policy Number:** 021

#### Overview

The purpose of this document is to describe the guidelines Mass General Brigham Health Plan utilizes to determine treatments that are considered experimental and investigational.

#### Coverage Guidelines

Mass General Brigham Health Plan covers services, procedures, devices, biologic products, and drugs (collectively “treatment”) when there is sufficient scientific evidence to support their use or when the treatment is required by regulation.

The following guidelines are utilized to determine the extent to which scientific evidence is sufficient to support a treatment:

1. The treatment must have a final approval from the appropriate government regulatory bodies (for example, the Food and Drug Administration); and
2. The scientific evidence must demonstrate that conclusions pertaining to a treatment are based on sound scientific study methodology published in credible, peer-reviewed English-language journals. The following hierarchy of reliable evidence is used:
  - a. Systematic reviews and/or high-quality meta-analyses of randomized controlled trials with definitive results
  - b. Formal high-quality technology assessments
  - c. Well-designed, randomized, controlled, double-blind studies
  - d. Cohort studies
  - e. High quality case-control studies
  - f. Expert opinion from national professional medical societies or national medical policy organizations in the absence of definitive scientific data

Note: With respect to clinical studies, only those articles containing scientifically valid data and published in the credible, peer-reviewed medical and scientific literature shall be considered reliable evidence. Specifically, not included in the meaning of reliable evidence are reports, articles, or statements by providers or groups of providers containing only abstracts, anecdotal evidence, or personal professional opinions. Also, not included in the meaning of reliable evidence is when a provider or a number of providers have elected to adopt a device, medical treatment, or procedure as their personal treatment or procedure of choice or standard of practice.

3. The treatment must be proven to be safe and effective:
  - a. Beneficial effects on health outcomes must outweigh any harmful effects
  - b. Health outcomes are superior or comparable to established alternatives
  - c. Improvement in health outcomes have the potential to be realized outside the investigational setting
  - d. It is as cost effective as established treatments that produce similar outcomes

### **Medicare Variation**

Mass General Brigham Health Plan uses guidance from the Centers for Medicare and Medicaid Services (CMS) for coverage determinations for its Medicare Advantage plan members. National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), Local Coverage Articles (LCAs) and documentation included in the Medicare manuals are the basis for coverage determinations. When there is no guidance from CMS for the requested service, Mass General Brigham Health Plan’s medical policies are used for coverage determinations. **At the time of Mass General Brigham Health Plan’s most recent policy review, Medicare has no NCD or LCD for experimental or investigational treatments.**

### **MassHealth Variation**

Mass General Brigham Health Plan uses guidance from MassHealth for coverage determinations of its MassHealth ACO members. When there is no guidance from MassHealth for the requested service, Mass General Brigham Health Plan’s medical policies are used for coverage determinations. **At the time of Mass General Brigham Health Plan’s most recent policy review, MassHealth did not have medical necessity guidelines for experimental or investigational treatments.**

### **Exclusions**

No benefits or reimbursement are provided for health care charges that are received for, or related to, care that Mass General Brigham Health Plan considers experimental and investigational services or procedures.

### **Definitions**

Experimental or Investigational: A treatment, service, procedure, supply, device, biologic product, or drug (collectively “treatment”) is experimental or investigational when scientific evidence to support its use is insufficient.

### **Relevant Regulations**

Public Law 111 - 148 - Patient Protection and Affordable Care Act, Section 2709. Coverage for a Clinical Trial.

(a) COVERAGE. —

- (1) IN GENERAL. —If a group health plan or a health insurance issuer offering group or individual health insurance coverage provides coverage to a qualified individual, then such plan or issuer—
  - (A) may not deny the individual participation in the clinical trial referred to in subsection (b)(2);
  - (B) subject to subsection (c), may not deny (or limit or impose additional conditions on) the coverage of routine patient costs for items and services furnished in connection with participation in the trial; and
  - (C) may not discriminate against the individual on the basis of the individual’s participation in such trial.
- (2) ROUTINE PATIENT COSTS. —
  - (A) INCLUSION. —For purposes of paragraph (1)(B), subject to subparagraph (B), routine patient costs include all items and services consistent with the coverage provided in the plan (or coverage) that is typically covered for a qualified individual who is not enrolled in a clinical trial.
  - (B) EXCLUSION. —For purposes of paragraph (1)(B), routine patient costs does not include—
    - i. the investigational item, device, or service, itself;
    - ii. items and services that are provided solely to satisfy data collection and analysis needs and that are not used in the direct clinical management of the patient; or



- iii. a service that is clearly inconsistent with widely accepted and established standards of care for a particular diagnosis.
  - (3) **USE OF IN-NETWORK PROVIDERS.** —If one or more participating providers is participating in a clinical trial, nothing in paragraph (1) shall be construed as preventing a plan or issuer from requiring that a qualified individual participate in the trial through such a participating provider if the provider will accept the individual as a participant in the trial.
  - (4) **USE OF OUT-OF-NETWORK.** —Notwithstanding paragraph (3), paragraph (1) shall apply to a qualified individual participating in an approved clinical trial that is conducted outside the State in which the qualified individual resides.
- (b) **QUALIFIED INDIVIDUAL DEFINED.** —For purposes of subsection (a), the term ‘qualified individual’ means an individual who is a participant or beneficiary in a health plan or with coverage described in subsection (a)(1) and who meets the following conditions:
  - (1) The individual is eligible to participate in an approved clinical trial according to the trial protocol with respect to treatment of cancer or other life-threatening disease or condition.
  - (2) Either—
    - (A) the referring health care professional is a participating health care provider and has concluded that the individual’s participation in such trial would be appropriate based upon the individual meeting the conditions described in paragraph (1); or
    - (B) the participant or beneficiary provides medical and scientific information establishing that the individual’s participation in such trial would be appropriate based upon the individual meeting the conditions described in paragraph (1).
- (c) **LIMITATIONS ON COVERAGE.** —This section shall not be construed to require a group health plan, or a health insurance issuer offering group or individual health insurance coverage, to provide benefits for routine patient care services provided outside of the plan’s (or coverage’s) health care provider network unless out-of-network benefits are otherwise provided under the plan (or coverage).
- (d) **APPROVED CLINICAL TRIAL DEFINED.** —
  - (1) **IN GENERAL.** —In this section, the term ‘approved clinical trial’ means a phase I, phase II, phase III, or phase IV clinical trial that is conducted in relation to the prevention, detection, or treatment of cancer or other life-threatening disease or condition and is described in any of the following subparagraphs:
    - (A) **FEDERALLY FUNDED TRIALS.** —The study or investigation is approved or funded (which may include funding through in-kind contributions) by one or more of the following:
      - i. The National Institutes of Health.
      - ii. The Centers for Disease Control and Prevention.
      - iii. The Agency for Health Care Research and Quality.
      - iv. The Centers for Medicare & Medicaid Services.
      - v. cooperative group or center of any of the entities described in clauses (i) through (iv) or the Department of Defense or the Department of Veterans Affairs.
      - vi. A qualified non-governmental research entity identified in the guidelines issued by the National Institutes of Health for center support grants.
      - vii. Any of the following if the conditions described in paragraph (2) are met:
        - I. The Department of Veterans Affairs.
        - II. The Department of Defense.



III. The Department of Energy.

- (B) The study or investigation is conducted under an investigational new drug application reviewed by the Food and Drug Administration.
  - (C) The study or investigation is a drug trial that is exempt from having such an investigational new drug application.
- (2) CONDITIONS FOR DEPARTMENTS. —The conditions described in this paragraph, for a study or investigation conducted by a Department (“departments” as referenced above in vii.), are that the study or investigation has been reviewed and approved through a system of peer review that the Secretary (of the respective departments listed above in vii.) determines—
- (A) to be comparable to the system of peer review of studies and investigations used by the National Institutes of Health, and
  - (B) assures unbiased review of the highest scientific standards by qualified individuals who have no interest in the outcome of the review.
- (e) LIFE-THREATENING CONDITION DEFINED. —In this section, the term ‘life-threatening condition’ means any disease or condition from which the likelihood of death is probable unless the course of the disease or condition is interrupted.

General Laws of Massachusetts Part I, Title XXII Chapter 175: Section 47K –Off-label use drug use: cancer treatment

No individual policy of accident and sickness insurance issued pursuant to section one hundred and eight which provides coverage for prescription drugs, nor any group blanket policy of accident and sickness insurance issued pursuant to section one hundred and ten which provides coverage for prescription drugs, shall exclude coverage of any such drug used for the treatment of cancer on the grounds that the off-label use of the drug has not been approved by the United States Food and Drug Administration for that indication; provided, however, that such drug is recognized for treatment of such indication in one of the standard reference compendia, or in the medical literature, or by the commissioner under the provisions of section forty-seven L.

General Laws of Massachusetts Part I, Title XXII Chapter 175: Sections 47O –HIV/AIDS treatment; insurance coverage for certain off-label use of prescription drugs

No individual policy of accident and sickness insurance issued or renewed pursuant to section one hundred and eight, which provides coverage for prescription drugs, nor any group blanket policy of accident and sickness insurance issued pursuant to section one hundred and ten which provides coverage for prescription drugs, shall exclude coverage of any such drug for HIV/AIDS treatment on the grounds that the off-label use of the drug has not been approved by the federal food and drug administration for that indication, if such drug is recognized for treatment of such indication in one of the standard reference compendia, or in the medical literature, or by the commissioner under the provisions of section forty-seven P of this chapter.

General Laws of Massachusetts Chapter 176G: Section 4G. Off-label use of prescription drugs for HIV/AIDS treatment

Any individual or group health insurance maintenance contract which provides coverage for prescription drugs shall provide coverage for off-label uses of prescription drugs used in the treatment of HIV/AIDS as set forth in sections forty-seven O and forty-seven P of chapter one hundred and seventy-five.

The following CPT/HCPCS procedure codes are investigational and unproven and therefore not covered.

| Code  | Description  |
|-------|--|
| 15011 | Harvest of skin for skin cell suspension autograft; first 25 sq cm or less |



|       |   |
|-------|---|
| 15012 | Harvest of skin for skin cell suspension autograft; each additional 25 sq cm or part thereof (List separately in addition to code for primary procedure)  |
| 15013 | Preparation of skin cell suspension autograft, requiring enzymatic processing, manual mechanical disaggregation of skin cells, and filtration; first 25 sq cm or less of harvested skin   |
| 15014 | Preparation of skin cell suspension autograft, requiring enzymatic processing, manual mechanical disaggregation of skin cells, and filtration; each additional 25 sq cm of harvested skin or part thereof (List separately in addition to code for primary procedure)   |
| 15015 | Application of skin cell suspension autograft to wound and donor sites, including application of primary dressing, trunk, arms, legs; first 480 sq cm or less   |
| 15016 | Application of skin cell suspension autograft to wound and donor sites, including application of primary dressing, trunk, arms, legs; each additional 480 sq cm or part thereof (List separately in addition to code for primary procedure)   |
| 15017 | Application of skin cell suspension autograft to wound and donor sites, including application of primary dressing, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 480 sq cm or less   |
| 15018 | Application of skin cell suspension autograft to wound and donor sites, including application of primary dressing, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; each additional 480 sq cm or part thereof (List separately in addition to code for primary procedure) |
| 20560 | Needle insertion(s) without injection(s); 1 or 2 muscle(s)  |
| 20561 | Needle insertion(s) without injection(s); 3 or more muscles   |
| 22526 | Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single   |
| 22527 | Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; 1 or more additional levels (List separately in addition to code for primary procedure)  |
| 22860 | Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression); second interspace, lumbar (List separately in addition to code for primary procedure)  |
| 22867 | Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; single level   |
| 22868 | Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; second level (List separately in addition to code for primary procedure)   |
| 22869 | Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; single level  |
| 22870 | Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when  |



|       |   |
|-------|---|
|       | performed, lumbar; second level (List separately in addition to code for primary procedure)   |
| 27278 | Arthrodesis, sacroiliac joint, percutaneous, with image guidance, including placement of intra-articular implant(s) (eg, bone allograft[s], synthetic device[s]), without placement of transfixation device   |
| 30468 | Repair of nasal valve collapse with subcutaneous/submucosal lateral wall implant(s)   |
| 30469 | Repair of nasal valve collapse with low energy, temperature-controlled (ie, radiofrequency) subcutaneous/submucosal remodeling  |
| 31242 | Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve   |
| 31243 | Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve  |
| 32994 | Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; cryoablation  |
| 33274 | Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed |
| 33275 | Transcatheter removal of permanent leadless pacemaker, right ventricular  |
| 33276 | Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation, when performed                                      |
| 33277 | Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to code for primary procedure)  |
| 33278 | Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and lead(s)   |
| 33279 | Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) only   |
| 33280 | Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only  |
| 33281 | Repositioning of phrenic nerve stimulator transvenous lead(s)   |
| 33287 | Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator   |
| 33288 | Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)  |
| 33370 | Transcatheter placement and subsequent removal of cerebral embolic protection device(s), including arterial access, catheterization, imaging, and   |



|       |   |
|-------|---|
|       | radiological supervision and interpretation, percutaneous (List separately in addition to code for primary procedure)   |
| 33894 | Endovascular stent repair of coarctation of the ascending, transverse, or descending thoracic or abdominal aorta, involving stent placement; across major side branches   |
| 33895 | Endovascular stent repair of coarctation of the ascending, transverse, or descending thoracic or abdominal aorta, involving stent placement; not crossing major side branches   |
| 33897 | Percutaneous transluminal angioplasty of native or recurrent coarctation of the aorta   |
| 33900 | Percutaneous pulmonary artery revascularization by stent placement, initial; normal native connections, unilateral  |
| 33901 | Percutaneous pulmonary artery revascularization by stent placement, initial; normal native connections, bilateral   |
| 33902 | Percutaneous pulmonary artery revascularization by stent placement, initial; abnormal connections, unilateral   |
| 33903 | Percutaneous pulmonary artery revascularization by stent placement, initial; abnormal connections, bilateral  |
| 33904 | Percutaneous pulmonary artery revascularization by stent placement, each additional vessel or separate lesion, normal or abnormal connections (List separately in addition to code for primary procedure)   |
| 34717 | Endovascular repair of iliac artery at the time of aorto-iliac artery endograft placement by deployment of an iliac branched endograft including pre-procedure sizing and device selection, all ipsilateral selective iliac artery catheterization(s), all associated radiological supervision and interpretation, and all endograft extension(s) proximally to the aortic bifurcation and distally in the internal iliac, external iliac, and common femoral artery(ies), and treatment zone angioplasty/stenting, when performed, for rupture or other than rupture (eg, for aneurysm, pseudoaneurysm, dissection, arteriovenous malformation, penetrating ulcer, traumatic disruption), unilateral (List separately in addition to code for primary procedure) |
| 34718 | Endovascular repair of iliac artery, not associated with placement of an aorto-iliac artery endograft at the same session, by deployment of an iliac branched endograft, including pre-procedure sizing and device selection, all ipsilateral selective iliac artery catheterization(s), all associated radiological supervision and interpretation, and all endograft extension(s) proximally to the aortic bifurcation and distally in the internal iliac, external iliac, and common femoral artery(ies), and treatment zone angioplasty/stenting, when performed, for other than rupture (eg, for aneurysm, pseudoaneurysm, dissection, arteriovenous malformation, penetrating ulcer), unilateral  |
| 34839 | Physician planning of a patient-specific fenestrated visceral aortic endograft requiring a minimum of 90 minutes of physician time  |
| 36836 | Percutaneous arteriovenous fistula creation, upper extremity, single access of both the peripheral artery and peripheral vein, including fistula maturation procedures (eg, transluminal balloon angioplasty, coil embolization) when   |



|       |   |
|-------|---|
|       | performed, including all vascular access, imaging guidance and radiologic supervision and interpretation  |
| 36837 | Percutaneous arteriovenous fistula creation, upper extremity, separate access sites of the peripheral artery and peripheral vein, including fistula maturation procedures (eg, transluminal balloon angioplasty, coil embolization) when performed, including all vascular access, imaging guidance and radiologic supervision and interpretation |
| 43257 | Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease  |
| 43284 | Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed  |
| 43285 | Removal of esophageal sphincter augmentation device   |
| 43290 | Esophagogastroduodenoscopy, flexible, transoral; with deployment of intragastric bariatric balloon  |
| 43291 | Esophagogastroduodenoscopy, flexible, transoral; with removal of intragastric bariatric balloon(s)  |
| 43497 | Lower esophageal myotomy, transoral (ie, peroral endoscopic myotomy [POEM])   |
| 43842 | Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty   |
| 43843 | Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty  |
| 51721 | Insertion of transurethral ablation transducer for delivery of thermal ultrasound for prostate tissue ablation, including suprapubic tube placement during the same session and placement of an endorectal cooling device, when performed   |
| 52284 | Cystourethroscopy, with mechanical urethral dilation and urethral therapeutic drug delivery by drug-coated balloon catheter for urethral stricture or stenosis, male, including fluoroscopy, when performed   |
| 53451 | Periurethral transperineal adjustable balloon continence device; bilateral insertion, including cystourethroscopy and imaging guidance  |
| 53452 | Periurethral transperineal adjustable balloon continence device; unilateral insertion, including cystourethroscopy and imaging guidance   |
| 53453 | Periurethral transperineal adjustable balloon continence device; removal, each balloon  |
| 53454 | Periurethral transperineal adjustable balloon continence device; percutaneous adjustment of balloon(s) fluid volume   |
| 53865 | Cystourethroscopy with insertion of temporary device for ischemic remodeling (ie, pressure necrosis) of bladder neck and prostate   |
| 53866 | Catheterization with removal of temporary device for ischemic remodeling (ie, pressure necrosis) of bladder neck and prostate   |
| 55880 | Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance  |





|       |  |
|-------|--|
| 55881 | Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation;   |
| 55882 | Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation; with insertion of transurethral ultrasound transducer for delivery of thermal ultrasound, including suprapubic tube placement and placement of an endorectal cooling device, when performed |
| 57465 | Computer-aided mapping of cervix uteri during colposcopy, including optical dynamic spectral imaging and algorithmic quantification of the acetowhitening effect (List separately in addition to code for primary procedure)   |
| 62263 | Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 2 or more days   |
| 62264 | Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 1 day  |
| 64454 | Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed   |
| 64596 | Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array   |
| 64597 | Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; each additional electrode array (List separately in addition to code for primary procedure)   |
| 64598 | Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator  |
| 64624 | Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed   |
| 64722 | Decompression; unspecified nerve(s) (specify)  |
| 66683 | Implantation of iris prosthesis, including suture fixation and repair or removal of iris, when performed   |
| 68841 | Insertion of drug-eluting implant, including punctal dilation when performed, into lacrimal canaliculus, each  |
| 76145 | Medical physics dose evaluation for radiation exposure that exceeds institutional review threshold, including report   |
| 77089 | Trabecular bone score (TBS), structural condition of the bone microarchitecture; using dual X-ray absorptiometry (DXA) or other imaging data on gray-scale variogram, calculation, with interpretation and report on fracture-risk   |
| 77090 | Trabecular bone score (TBS), structural condition of the bone microarchitecture; technical preparation and transmission of data for analysis to be performed elsewhere   |



|       |  |
|-------|--|
| 77091 | Trabecular bone score (TBS), structural condition of the bone microarchitecture; technical calculation only  |
| 77092 | Trabecular bone score (TBS), structural condition of the bone microarchitecture; interpretation and report on fracture-risk only by other qualified health care professional |
| 80204 | Methotrexate   |
| 80220 | Hydroxychloroquine   |
| 81168 | CCND1/IGH (t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative and quantitative, if performed   |
| 81191 | NTRK1 (neurotrophic receptor tyrosine kinase 1) (eg, solid tumors) translocation analysis  |
| 81192 | NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis  |
| 81193 | NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis  |
| 81194 | NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis   |
| 81278 | IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative |
| 81279 | JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13)   |
| 81283 | IFNL3 (interferon, lambda 3) (eg, drug response), gene analysis, rs12979860 variant  |
| 81328 | SLCO1B1 (solute carrier organic anion transporter family, member 1B1) (eg, adverse drug reaction), gene analysis, common variant(s) (eg, *5)                                 |
| 81338 | MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R)                          |
| 81339 | MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10  |
| 81346 | TYMS (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drug metabolism), gene analysis, common variant(s) (eg, tandem repeat variant)  |
| 81347 | SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L)         |
| 81348 | SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L)                    |
| 81352 | TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology)  |
| 81357 | U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P)         |



|       |   |
|-------|---|
| 81360 | ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs)   |
| 81490 | Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score   |
| 81517 | Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years |
| 81525 | Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score   |
| 81535 | Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; first single drug or drug combination   |
| 81536 | Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; each additional single drug or drug combination (List separately in addition to code for primary procedure)   |
| 81540 | Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype       |
| 81541 | Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score  |
| 81560 | Transplantation medicine (allograft rejection, pediatric liver and small bowel), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score  |
| 82233 | Beta-amyloid; 1-40 (Abeta 40)   |
| 82234 | Beta-amyloid; 1-42 (Abeta 42)   |
| 82681 | Estradiol; free, direct measurement (eg, equilibrium dialysis)  |
| 83529 | Interleukin-6 (IL-6) (new code eff 1/1/2022)  |
| 83884 | Neurofilament light chain (NfL)   |
| 84393 | Tau, phosphorylated (eg, pTau 181, pTau 217), each  |
| 84394 | Tau, total (tTau)   |
| 86015 | Actin (smooth muscle) antibody (ASMA), each   |
| 86036 | Antineutrophil cytoplasmic antibody (ANCA); screen, each antibody   |
| 86037 | Antineutrophil cytoplasmic antibody (ANCA); titer, each antibody  |



|       |   |
|-------|---|
| 86053 | Aquaporin-4 (neuromyelitis optica [NMO]) antibody; flow cytometry (ie, fluorescence-activated cell sorting [FACS]), each  |
| 86231 | Endomysial antibody (EMA), each immunoglobulin (Ig) class   |
| 86357 | Natural killer (NK) cells, total count  |
| 86362 | Myelin oligodendrocyte glycoprotein (MOG-IgG1) antibody; cell-based immunofluorescence assay (CBA), each  |
| 86363 | Myelin oligodendrocyte glycoprotein (MOG-IgG1) antibody; flow cytometry (ie, fluorescence-activated cell sorting [FACS]), each  |
| 86596 | Voltage-gated calcium channel antibody, each  |
| 87467 | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; Hepatitis B surface antigen (HBsAg), quantitative |
| 87913 | Infectious agent genotype analysis by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region(s)   |
| 90584 | Dengue vaccine, quadrivalent, live, 2 dose schedule, for subcutaneous use   |
| 90593 | Chikungunya virus vaccine, recombinant, for intramuscular use   |
| 90637 | Influenza virus vaccine, quadrivalent (qIRV), mRNA; 30 mcg/0.5 mL dosage, for intramuscular use   |
| 90638 | Influenza virus vaccine, quadrivalent (qIRV), mRNA; 60 mcg/0.5 mL dosage, for intramuscular use   |
| 90678 | Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use   |
| 90683 | Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use  |
| 90880 | Hypnotherapy  |
| 91113 | Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), colon, with interpretation and report   |
| 91308 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use  |
| 91314 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use   |
| 91315 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use  |
| 92145 | Corneal hysteresis determination, by air impulse stimulation, unilateral or bilateral, with interpretation and report   |
| 92972 | Percutaneous transluminal coronary lithotripsy (List separately in addition to code for primary procedure)  |



|       |   |
|-------|---|
| 93050 | Arterial pressure waveform analysis for assessment of central arterial pressures, includes obtaining waveform(s), digitization and application of nonlinear mathematical transformations to determine central arterial pressures and augmentation index, with interpretation and report, upper extremity artery, non-invasive |
| 93150 | Therapy activation of implanted phrenic nerve stimulator system, including all interrogation and programming  |
| 93151 | Interrogation and programming (minimum one parameter) of implanted phrenic nerve stimulator system  |
| 93152 | Interrogation and programming of implanted phrenic nerve stimulator system during polysomnography   |
| 93153 | Interrogation without programming of implanted phrenic nerve stimulator system  |
| 93264 | Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care   |
| 93356 | Myocardial strain imaging using speckle tracking-derived assessment of myocardial mechanics (List separately in addition to codes for echocardiography imaging)   |
| 93702 | Bioimpedance spectroscopy (BIS), extracellular fluid analysis for lymphedema assessment(s)  |
| 93740 | Temperature gradient studies  |
| 95919 | Quantitative pupillometry with physician or other qualified health care professional interpretation and report, unilateral or bilateral   |
| 96931 | Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition and interpretation and report, first lesion  |
| 96932 | Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition only, first lesion   |
| 96933 | Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; interpretation and report only, first lesion   |
| 96934 | Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition and interpretation and report, each additional lesion (List separately in addition to code for primary procedure)  |
| 96935 | Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition only, each additional lesion (List separately in addition to code for primary procedure)   |
| 96936 | Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; interpretation and report only, each additional lesion (List separately in addition to code for primary procedure)   |
| 97037 | Application of a modality to 1 or more areas; low-level laser therapy (ie, nonthermal and non-ablative) for post-operative pain reduction   |
| S3650 | diagnostic test of saliva to determine hormone levels (estrogen, testosterone) and bio identical hormone replacement therapy  |



|       |   |
|-------|---|
| 0006M | Oncology (hepatic), mRNA expression levels of 161 genes, utilizing fresh hepatocellular carcinoma tumor tissue, with alpha-fetoprotein level, algorithm reported as a risk classifier   |
| 0007M | Oncology (gastrointestinal neuroendocrine tumors), real-time PCR expression analysis of 51 genes, utilizing whole peripheral blood, algorithm reported as a nomogram of tumor disease index   |
| 0018M | Transplantation medicine (allograft rejection, renal), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score  |
| 0054T | Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance based on fluoroscopic images (List separately in addition to code for primary procedure)  |
| 0055T | Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance based on CT/MRI images (List separately in addition to code for primary procedure)  |
| 0071T | Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume less than 200 cc of tissue  |
| 0072T | Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume greater or equal to 200 cc of tissue  |
| 0075T | Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; initial vessel  |
| 0076T | Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; each additional vessel (List separately in addition to code for primary procedure)  |
| 0086U | Infectious disease (bacterial and fungal), organism identification, blood culture, using rRNA FISH, 6 or more organism targets, reported as positive or negative with phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility  |
| 0091U | Oncology (colorectal) screening, cell enumeration of circulating tumor cells, utilizing whole blood, algorithm, for the presence of adenoma or cancer, reported as a positive or negative result  |
| 0092U | Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as risk score for likelihood of malignancy  |
| 0093U | Prescription drug monitoring, evaluation of 65 common drugs by LC-MS/MS, urine, each drug reported detected or not detected   |
| 0095T | Removal of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical (List separately in addition to code for primary procedure)   |
| 0095U | Inflammation (eosinophilic esophagitis), ELISA analysis of eotaxin-3 (CCL26 [C-C motif chemokine ligand 26]) and major basic protein (PRG2 [proteoglycan 2, pro eosinophil major basic protein]), specimen obtained by swallowed nylon string, algorithm reported as predictive probability index for active eosinophilic esophagitis |



|       |   |
|-------|---|
| 0096U | Human papillomavirus (HPV), high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), male urine  |
| 0098T | Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical (List separately in addition to code for primary procedure)  |
| 0100T | Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intra-ocular retinal electrode array, with vitrectomy   |
| 0101T | Extracorporeal shock wave involving musculoskeletal system, not otherwise specified; high energy<br>SpaceOAR  |
| 0102T | Extracorporeal shock wave, high energy, performed by a physician, requiring anesthesia other than local, involving lateral humeral epicondyle<br>SpaceOAR   |
| 0105U | Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD) |
| 0106T | Quantitative sensory testing (QST), testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation   |
| 0106U | Gastric emptying, serial collection of 7 timed breath specimens, non-radioisotope carbon-13 (13C) spirulina substrate, analysis of each specimen by gas isotope ratio mass spectrometry, reported as rate of 13CO2 excretion  |
| 0107T | Quantitative sensory testing (QST), testing and interpretation per extremity; using vibration stimuli to assess large diameter fiber sensation  |
| 0107U | Clostridium difficile toxin(s) antigen detection by immunoassay technique, stool, qualitative, multiple-step method   |
| 0108T | Quantitative sensory testing (QST), testing and interpretation per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia  |
| 0108U | Gastroenterology (Barrett's esophagus), whole slide-digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer  |
| 0109T | Quantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia  |
| 0109U | Infectious disease (Aspergillus species), real-time PCR for detection of DNA from 4 species (A. fumigatus, A. terreus, A. niger, and A. flavus), blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species   |
| 0110T | Quantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensation   |
| 0110U | Prescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum  |



|       |   |
|-------|---|
|       | or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected  |
| 0112U | Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene  |
| 0115U | Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected  |
| 0116U | Prescription drug monitoring, enzyme immunoassay of 35 or more drugs confirmed with LC-MS/MS, oral fluid, algorithm results reported as a patient-compliance measurement with risk of drug to drug interactions for prescribed medications  |
| 0117U | Pain management, analysis of 11 endogenous analytes (methylmalonic acid, xanthurenic acid, homocysteine, pyroglutamic acid, vanilmandelate, 5-hydroxyindoleacetic acid, hydroxymethylglutarate, ethylmalonate, 3-hydroxypropyl mercapturic acid (3-HPMA), quinolinic acid, kynurenic acid), LC-MS/MS, urine, algorithm reported as a pain-index score with likelihood of atypical biochemical function associated with pain |
| 0119U | Cardiology, ceramides by liquid chromatography–tandem mass spectrometry, plasma, quantitative report with risk score for major cardiovascular events  |
| 0120T | Ablation, cryosurgical, of fibroadenoma, including ultrasound guidance, each fibroadenoma   |
| 0121U | Sickle cell disease, microfluidic flow adhesion (VCAM-1), whole blood   |
| 0122U | Sickle cell disease, microfluidic flow adhesion (P-Selectin), whole blood   |
| 0123U | Mechanical fragility, RBC, shear stress and spectral analysis profiling   |
| 0133T | Upper gastrointestinal endoscopy, including esophagus, stomach, and either the duodenum and/or jejunum as appropriate, with injection of implant material into and along the muscle of the lower esophageal sphincter (eg, for treatment of gastroesophageal reflux disease)  |
| 0135T | Ablation, renal tumor(s), unilateral, percutaneous, cryotherapy   |
| 0140U | Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected   |
| 0141U | Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, DNA (20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected  |
| 0142U | Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan Candida target), amplified probe technique, each target reported as detected or not detected  |





|       |   |
|-------|---|
| 0143U | Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service   |
| 0144A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose                              |
| 0144U | Drug assay, definitive, 160 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service   |
| 0145U | Drug assay, definitive, 65 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service    |
| 0146U | Drug assay, definitive, 80 or more drugs or metabolites, urine, by quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service |
| 0147U | Drug assay, definitive, 85 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service    |
| 0148U | Drug assay, definitive, 100 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service   |
| 0149U | Drug assay, definitive, 60 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service    |
| 0150U | Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service   |
| 0152U | Infectious disease (bacteria, fungi, parasites, and DNA viruses), DNA, PCR and next-generation sequencing, plasma, detection of >1,000 potential microbial organisms for significant positive pathogens   |
| 0154U | FGFR3 (fibroblast growth factor receptor 3) gene analysis (ie, p.R248C [c.742C>T], p.S249C [c.746C>G], p.G370C [c.1108G>T], p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3-TACC3v3)  |
| 0155U | PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) (eg, breast cancer) gene analysis (ie, p.C420R, p.E542K, p.E545A, p.E545D)   |



|       |   |
|-------|---|
|       | [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y)   |
| 0163U | Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [TDGF-1, Cripto-1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRC-screening compliance) using a proprietary algorithm and reported as likelihood of CRC or advanced adenomas |
| 0164T | Removal of total disc arthroplasty, (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)  |
| 0164U | Gastroenterology (irritable bowel syndrome [IBS]), immunoassay for anti-CdtB and anti-vinculin antibodies, utilizing plasma, algorithm for elevated or not elevated qualitative results   |
| 0165T | Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)  |
| 0165U | Peanut allergen-specific IgE and quantitative assessment of 64 epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope results and interpretation   |
| 0166U | Liver disease, 10 biochemical assays (?2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation  |
| 0167U | Gonadotropin, chorionic (hCG), immunoassay with direct optical observation, blood   |
| 0174T | Computer-aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest radiograph(s), performed concurrent with primary interpretation (List separately in addition to code for primary procedure)  |
| 0174U | Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents  |
| 0175T | Computer-aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest radiograph(s), performed remote from primary interpretation  |
| 0176U | Cytotoxic distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (ie, ELISA)  |
| 0177U | Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) gene analysis of 11 gene variants utilizing plasma, reported as PIK3CA gene mutation status  |



|       |  |
|-------|--|
| 0178U | Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, report of minimum eliciting exposure for a clinical reaction   |
| 0180U | Red cell antigen (ABO blood group) genotyping (ABO), gene analysis Sanger/chain termination/conventional sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene, including subtyping, 7 exons |
| 0181U | Red cell antigen (Colton blood group) genotyping (CO), gene analysis, AQP1 (aquaporin 1 [Colton blood group]) exon 1   |
| 0182U | Red cell antigen (Cromer blood group) genotyping (CROM), gene analysis, CD55 (CD55 molecule [Cromer blood group]) exons 1-10   |
| 0183U | Red cell antigen (Diego blood group) genotyping (DI), gene analysis, SLC4A1 (solute carrier family 4 member 1 [Diego blood group]) exon 19   |
| 0184U | Red cell antigen (Dombrock blood group) genotyping (DO), gene analysis, ART4 (ADP-ribosyltransferase 4 [Dombrock blood group]) exon 2  |
| 0185U | Red cell antigen (H blood group) genotyping (FUT1), gene analysis, FUT1 (fucosyltransferase 1 [H blood group]) exon 4  |
| 0186U | Red cell antigen (H blood group) genotyping (FUT2), gene analysis, FUT2 (fucosyltransferase 2) exon 2  |
| 0187U | Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, ACKR1 (atypical chemokine receptor 1 [Duffy blood group]) exons 1-2   |
| 0188U | Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, GYPC (glycophorin C [Gerbich blood group]) exons 1-4  |
| 0189U | Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA (glycophorin A [MNS blood group]) introns 1, 5, exon 2   |
| 0190U | Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB (glycophorin B [MNS blood group]) introns 1, 5, pseudoexon 3   |
| 0191U | Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44 (CD44 molecule [Indian blood group]) exons 2, 3, 6  |
| 0192U | Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1 (solute carrier family 14 member 1 [Kidd blood group]) gene promoter, exon 9   |
| 0193U | Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2 (ATP binding cassette subfamily G member 2 [Junior blood group]) exons 2-26  |
| 0194U | Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL (Kell metallo-endopeptidase [Kell blood group]) exon 8  |
| 0195U | KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon 13)  |
| 0196U | Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, BCAM (basal cell adhesion molecule [Lutheran blood group]) exon 3  |
| 0197U | Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, ICAM4 (intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]) exon 1  |
| 0198T | Measurement of ocular blood flow by repetitive intraocular pressure sampling, with interpretation and report   |



|       |   |
|-------|---|
| 0198U | Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, RHD (Rh blood group D antigen) exons 1-10 and RHCE (Rh blood group CcEe antigens) exon 5   |
| 0199U | Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAP (erythroblast membrane associated protein [Scianna blood group]) exons 4, 12   |
| 0200T | Percutaneous sacral augmentation (sacroplasty), unilateral injection(s), including the use of a balloon or mechanical device, when used, 1 or more needles, includes imaging guidance and bone biopsy, when performed   |
| 0200U | Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK (X-linked Kx blood group) exons 1-3  |
| 0201T | Percutaneous sacral augmentation (sacroplasty), bilateral injections, including the use of a balloon or mechanical device, when used, 2 or more needles, includes imaging guidance and bone biopsy, when performed  |
| 0201U | Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2   |
| 0202T | Posterior vertebral joint(s) arthroplasty (eg, facet joint[s] replacement), including facetectomy, laminectomy, foraminotomy, and vertebral column fixation, injection of bone cement, when performed, including fluoroscopy, single level, lumbar spine  |
| 0206U | Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease                                      |
| 0207T | Evacuation of meibomian glands, automated, using heat and intermittent pressure, unilateral   |
| 0207U | Neurology (Alzheimer disease); quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure) |
| 0209T | Pure tone audiometry (threshold), automated; air and bone   |
| 0210T | Speech audiometry threshold, automated  |
| 0210U | Syphilis test, non-treponemal antibody, immunoassay, quantitative (RPR)   |
| 0211T | Speech audiometry threshold, automated; with speech recognition   |
| 0212T | Comprehensive audiometry threshold evaluation and speech recognition (0209T, 0211T combined), automated   |
| 0213T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; single level  |
| 0214T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; second level (List separately in addition to code for primary procedure)  |
| 0215T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound   |



|       |  |
|-------|--|
|       | guidance, cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure)  |
| 0216T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; single level   |
| 0217T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; second level (List separately in addition to code for primary procedure)   |
| 0218T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure)                            |
| 0219T | Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; cervical   |
| 0219U | Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (ie, protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility  |
| 0220T | Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; thoracic   |
| 0221T | Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; lumbar   |
| 0221U | Red cell antigen (ABO blood group) genotyping (ABO), gene analysis, next-generation sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene  |
| 0222T | Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; each additional vertebral segment (List separately in addition to code for primary procedure)                                    |
| 0222U | Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis, next-generation sequencing, RH proximal promoter, exons 1-10, portions of introns 2-3  |
| 0223U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected |
| 0224U | Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed   |
| 0226U | Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum  |



|       |   |
|-------|---|
| 0227U | Drug assay, presumptive, 30 or more drugs or metabolites, urine, liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, includes sample validation   |
| 0232T | Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed   |
| 0234T | Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; renal artery  |
| 0235T | Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; visceral artery (except renal), each vessel   |
| 0236T | Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; abdominal aorta   |
| 0237T | Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; brachiocephalic trunk and branches, each vessel   |
| 0238T | Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; iliac artery, each vessel   |
| 0243U | Obstetrics (preeclampsia), biochemical assay of placental-growth factor, time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia   |
| 0247U | Obstetrics (preterm birth), insulin-like growth factor-binding protein 4 (IBP4), sex hormone-binding globulin (SHBG), quantitative measurement by LC-MS/MS, utilizing maternal serum, combined with clinical data, reported as predictive-risk stratification for spontaneous preterm birth |
| 0248U | Oncology (brain), spheroid cell culture in a 3D microenvironment, 12 drug panel, tumor-response prediction for each drug  |
| 0249U | Oncology (breast), semiquantitative analysis of 32 phosphoproteins and protein analytes, includes laser capture microdissection, with algorithmic analysis and interpretative report  |
| 0251U | Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma   |
| 0253T | Insertion of anterior segment aqueous drainage device, without extraocular reservoir, internal approach, into the suprachoroidal space  |
| 0255U | Andrology (infertility), sperm-capacitation assessment of ganglioside GM1 distribution patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of capacitated sperm and probability of generating a pregnancy score   |
| 0256U | Trimethylamine/trimethylamine N-oxide (TMA/TMAO) profile, tandem mass spectrometry (MS/MS), urine, with algorithmic analysis and interpretive report  |
| 0257U | Very long chain acyl-coenzyme A (CoA) dehydrogenase (VLCAD), leukocyte enzyme activity, whole blood   |
| 0259U | Nephrology (chronic kidney disease), nuclear magnetic resonance spectroscopy measurement of myo-inositol, valine, and creatinine, algorithmically combined  |



|       |  |
|-------|--|
|       | with cystatin C (by immunoassay) and demographic data to determine estimated glomerular filtration rate (GFR), serum, quantitative   |
| 0261U | Oncology (colorectal cancer), image analysis with artificial intelligence assessment of 4 histologic and immunohistochemical features (CD3 and CD8 within tumor-stroma border and tumor core), tissue, reported as immune response and recurrence-risk score   |
| 0263T | Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure including unilateral or bilateral bone marrow harvest  |
| 0263U | Neurology (autism spectrum disorder [ASD]), quantitative measurements of 16 central carbon metabolites (ie, $\alpha$ ketoglutarate, alanine, lactate, phenylalanine, pyruvate, succinate, carnitine, citrate, fumarate, hypoxanthine, inosine, malate, S-sulfocysteine, taurine, urate, and xanthine), liquid chromatography tandem mass spectrometry (LC-MS/MS), plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD) |
| 0264T | Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure excluding bone marrow harvest  |
| 0265T | Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; unilateral or bilateral bone marrow harvest only for intramuscular autologous bone marrow cell therapy  |
| 0266T | Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)  |
| 0267T | Implantation or replacement of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)  |
| 0268T | Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)   |
| 0269T | Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)  |
| 0270T | Revision or removal of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)  |
| 0271T | Revision or removal of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)   |
| 0272T | Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with  |



|       |  |
|-------|--|
|       | interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day);  |
| 0273T | Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day); with programming |
| 0274T | Percutaneous laminotomy/laminectomy (intradiscal approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy) any method under indirect image guidance (e.g., fluoroscopic, CT), with or without the use of an endoscope, single or multiple levels, unilateral or bilateral; cervical or thoracic   |
| 0275T | Percutaneous laminotomy/laminectomy (intradiscal approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy) any method under indirect image guidance (e.g., fluoroscopic, CT), with or without the use of an endoscope, single or multiple levels, unilateral or bilateral; cervical or thoracic, lumbar   |
| 0275U | Hematology (heparin-induced thrombocytopenia), platelet antibody reactivity by flow cytometry, serum   |
| 0278T | Transcutaneous electrical modulation pain reprocessing (eg, scrambler therapy), each treatment session (includes placement of electrodes)  |
| 0279U | Hematology (von Willebrand disease [VWD]), von Willebrand factor (VWF) and collagen III binding by enzyme-linked immunosorbent assays (ELISA), plasma, report of collagen III binding  |
| 0280U | Hematology (von Willebrand disease [VWD]), von Willebrand factor (VWF) and collagen IV binding by enzyme-linked immunosorbent assays (ELISA), plasma, report of collagen IV binding  |
| 0281U | Hematology (von Willebrand disease [VWD]), von Willebrand propeptide, enzyme-linked immunosorbent assays (ELISA), plasma, diagnostic report of von Willebrand factor (VWF) propeptide antigen level  |
| 0283U | von Willebrand factor (VWF), type 2B, platelet-binding evaluation, radioimmunoassay, plasma  |
| 0284U | von Willebrand factor (VWF), type 2N, factor VIII and VWF binding evaluation, enzyme-linked immunosorbent assays (ELISA), plasma   |
| 0295U | Oncology (breast ductal carcinoma in situ), protein expression profiling by immunohistochemistry of 7 proteins (COX2, FOXA1, HER2, Ki-67, p16, PR, SIAH2), with 4 clinicopathologic factors (size, age, margin status, palpability), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a recurrence risk score   |





|       |  |
|-------|--|
| 0301U | Infectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR);   |
| 0302U | Infectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR); following liquid enrichment   |
| 0303U | Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxic  |
| 0304U | Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxic normoxic   |
| 0305U | Hematology, red blood cell (RBC) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index  |
| 0308U | Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for obstructive CAD   |
| 0309U | Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for major adverse cardiac event   |
| 0310U | Pediatrics (vasculitis, Kawasaki disease [KD]), analysis of 3 biomarkers (NT-proBNP, C-reactive protein, and T-uptake), plasma, algorithm reported as a risk score for KD  |
| 0311U | Infectious disease (bacterial), quantitative antimicrobial susceptibility reported as phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility for each organisms identified   |
| 0312U | Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment |
| 0316U | Borrelia burgdorferi (Lyme disease), OspA protein evaluation, urine  |
| 0321U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique   |
| 0322U | Neurology (autism spectrum disorder [ASD]), quantitative measurements of 14 acyl carnitines and microbiome-derived metabolites, liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma, results reported as negative or positive for risk of metabolic subtypes associated with ASD  |
| 0323U | infectious agent detection by nucleic acid (DNA and RNA), central nervous system pathogen, metagenomic next-generation sequencing, cerebrospinal fluid (CSF), identification of pathogenic bacteria, viruses, parasites, or fungi  |



|       |   |
|-------|---|
| 0324U | Oncology (ovarian), spheroid cell culture, 4-drug panel (carboplatin, doxorubicin, gemcitabine, paclitaxel), tumor chemotherapy response prediction for each drug   |
| 0325U | Oncology (ovarian), spheroid cell culture, poly (ADP-ribose) polymerase (PARP) inhibitors (niraparib, olaparib, rucaparib, velparib), tumor response prediction for each drug   |
| 0327U | Fetal aneuploidy (trisomy 13, 18, and 21), DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy, includes sex reporting, if performed   |
| 0328U | Drug assay, definitive, 120 or more drugs and metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS), includes specimen validity and algorithmic analysis describing drug or metabolite and presence or absence of risks for a significant patient-adverse event, per date of service  |
| 0330U | Infectious agent detection by nucleic acid (DNA or RNA), vaginal pathogen panel, identification of 27 organisms, amplified probe technique, vaginal swab  |
| 0331T | Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment  |
| 0332T | Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment; with tomographic SPECT  |
| 0333T | Visual evoked potential, screening of visual acuity, automated  |
| 0335T | Extra-osseous subtalar joint implant for talotarsal stabilization   |
| 0337U | Oncology (plasma cell disorders and myeloma), circulating plasma cell immunologic selection, identification, morphological characterization, and enumeration of plasma cells based on differential CD138, CD38, CD19, and CD45 protein biomarker expression, peripheral blood   |
| 0338T | Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral |
| 0338U | Oncology (solid tumor), circulating tumor cell selection, identification, morphological characterization, detection and enumeration based on differential EpCAM, cytokeratins 8, 18, and 19, and CD45 protein biomarkers, and quantification of HER2 protein biomarker-expressing cells, peripheral blood   |
| 0339T | Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral  |
| 0342U | Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline   |



|       |  |
|-------|--|
| 0344U | Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), serum, reported as at-risk for nonalcoholic steatohepatitis (NASH) or not NASH   |
| 0345T | Transcatheter mitral valve repair percutaneous approach via the coronary sinu  |
| 0346U | Beta amyloid, AB40 and AB42 by liquid chromatography with tandem mass spectrometry (LC-MS/MS), ratio, plasma   |
| 0347T | Placement of interstitial device(s) in bone for radiostereometric analysis (RSA)   |
| 0348T | Radiologic examination, radiostereometric analysis (RSA); spine, (includes, cervical, thoracic and lumbosacral, when performed)  |
| 0349T | Radiologic examination, radiostereometric analysis (RSA); upper extremity(ies), (includes shoulder, elbow and wrist, when performed)   |
| 0350T | Radiologic examination, radiostereometric analysis (RSA); lower extremity(ies), (includes hip, proximal femur, knee and ankle, when performed)   |
| 0351U | Infectious disease (bacterial or viral), biochemical assays, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10), and C-reactive protein, serum, algorithm reported as likelihood of bacterial infection  |
| 0352U | Infectious disease (bacterial vaginosis and vaginitis), multiplex amplified probe technique, for detection of bacterial vaginosis-associated bacteria (BVAB-2, Atopobium vaginae, and Megasphaera type 1), algorithm reported as detected or not detected and separate detection of Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei, and trichomonas vaginalis, vaginal-fluid specimen, each result reported as detected or not detected |
| 0353U | Infectious agent detection by nucleic acid (DNA), Chlamydia trachomatis and Neisseria gonorrhoeae, multiplex amplified probe technique, urine, vaginal, pharyngeal, or rectal, each pathogen reported as detected or not detected  |
| 0354U | Human papilloma virus (HPV), high-risk types (ie, 16, 18, 31, 33, 45, 52 and 58) qualitative mRNA expression of E6/E7 by quantitative polymerase chain reaction (qPCR)   |
| 0357U | Oncology (melanoma), artificial intelligence (AI)-enabled quantitative mass spectrometry analysis of 142 unique pairs of glycopeptide and product fragments, plasma, prognostic, and predictive algorithm reported as likely, unlikely, or uncertain benefit from immunotherapy agents   |
| 0358T | Bioelectrical impedance analysis whole body composition assessment, with interpretation and report   |
| 0358U | Neurology (mild cognitive impairment), analysis of $\beta$ -amyloid 1-42 and 1-40, chemiluminescence enzyme immunoassay, cerebral spinal fluid, reported as positive, likely positive, or negative   |
| 0359U | Oncology (prostate cancer), analysis of all prostate-specific antigen (PSA) structural isoforms by phase separation and immunoassay, plasma, algorithm reports risk of cancer  |



|       |  |
|-------|--|
| 0360U | Oncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7 autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and HuD), plasma, algorithm reported as a categorical result for risk of malignancy  |
| 0361U | Neurofilament light chain, digital immunoassay, plasma, quantitative   |
| 0365U | Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, algorithm reported as a probability of bladder cancer   |
| 0366U | Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, algorithm reported as a probability of recurrent bladder cancer   |
| 0367U | Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection   |
| 0369U | Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique  |
| 0370U | Infectious agent detection by nucleic acid (DNA and RNA), surgical wound pathogens, 34 microorganisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, wound swab   |
| 0371U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, DNA from 16 bacterial organisms and 1 fungal organism, multiplex amplified probe technique via quantitative polymerase chain reaction (qPCR), urine                                |
| 0372U | Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe technique, urine, reported as an antimicrobial stewardship risk score  |
| 0373U | Infectious agent detection by nucleic acid (DNA and RNA), respiratory tract infection, 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes, multiplex amplified probe technique, upper or lower respiratory specimen   |
| 0374U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 21 bacterial and fungal organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, urine  |
| 0375U | Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [ie, transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score                      |
| 0376U | Oncology (prostate cancer), image analysis of at least 128 histologic features and clinical factors, prognostic algorithm determining the risk of distant metastases, and prostate cancer-specific mortality, includes predictive algorithm to androgen deprivation-therapy response, if appropriate |



|       |  |
|-------|--|
| 0377U | Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables)   |
| 0378T | Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional   |
| 0378U | RFC1 (replication factor C subunit 1), repeat expansion variant analysis by traditional and repeat-primed PCR, blood, saliva, or buccal swab   |
| 0379T | Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; technical support and patient instructions, surveillance, analysis, and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional |
| 0381U | Maple syrup urine disease monitoring by patient-collected blood card sample, quantitative measurement of allo-isoleucine, leucine, isoleucine, and valine, liquid chromatography with tandem mass spectrometry (LC-MS/MS)  |
| 0382U | Hyperphenylalaninemia monitoring by patient-collected blood card sample, quantitative measurement of phenylalanine and tyrosine, liquid chromatography with tandem mass spectrometry (LC-MS/MS)  |
| 0383U | Tyrosinemia type I monitoring by patient-collected blood card sample, quantitative measurement of tyrosine, phenylalanine, methionine, succinylacetone, nitisinone, liquid chromatography with tandem mass spectrometry (LC-MS/MS)   |
| 0384U | Nephrology (chronic kidney disease), carboxymethyllysine, methylglyoxal hydroimidazolone, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and HbA1c and estimated glomerular filtration rate (GFR), with risk score reported for predictive progression to high-stage kidney disease   |
| 0385U | Nephrology (chronic kidney disease), apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and insulin-like growth factor binding protein 3 (IGFBP3) by enzyme-linked immunoassay (ELISA), plasma, algorithm combining results with HDL, estimated glomerular filtration rate (GFR) and clinical data reported as a risk score for developing diabetic kidney disease                      |
| 0394T | High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed  |
| 0395T | High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed   |
| 0408T | Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator with transvenous electrodes   |
| 0409T | Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only  |



|       |   |
|-------|---|
| 0410T | Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; atrial electrode only  |
| 0411T | Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only   |
| 0412T | Removal of permanent cardiac contractility modulation system; pulse generator only  |
| 0413T | Removal of permanent cardiac contractility modulation system; transvenous electrode (atrial or ventricular)   |
| 0414T | Removal and replacement of permanent cardiac contractility modulation system pulse generator only   |
| 0415T | Repositioning of previously implanted cardiac contractility modulation transvenous electrode, (atrial or ventricular lead)  |
| 0416T | Relocation of skin pocket for implanted cardiac contractility modulation pulse generator  |
| 0417T | Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation system |
| 0418T | Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, implantable cardiac contractility modulation system   |
| 0419T | Destruction of neurofibroma, extensive (cutaneous, dermal extending into subcutaneous); face, head and neck, greater than 50 neurofibromas  |
| 0420T | Destruction of neurofibroma, extensive (cutaneous, dermal extending into subcutaneous); trunk and extremities, extensive, greater than 100 neurofib   |
| 0422T | Tactile breast imaging by computer-aided tactile sensors, unilateral or bilateral   |
| 0424T | Insertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement of right or left stimulation lead, sensing lead, implantable pulse generator)   |
| 0425T | Insertion or replacement of neurostimulator system for treatment of central sleep apnea; sensing lead only  |
| 0426T | Insertion or replacement of neurostimulator system for treatment of central sleep apnea; stimulation lead only  |
| 0427T | Insertion or replacement of neurostimulator system for treatment of central sleep apnea; pulse generator only   |
| 0427U | Monocyte distribution width, whole blood (List separately in addition to code for primary procedure)  |
| 0428T | Removal of neurostimulator system for treatment of central sleep apnea; pulse generator only  |
| 0429T | Removal of neurostimulator system for treatment of central sleep apnea; sensing lead only   |



|       |  |
|-------|--|
| 0429U | Human papillomavirus (HPV), oropharyngeal swab, 14 high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)  |
| 0430T | Removal of neurostimulator system for treatment of central sleep apnea; stimulation lead on  |
| 0430U | Gastroenterology, malabsorption evaluation of alpha-1-antitrypsin, calprotectin, pancreatic elastase and reducing substances, feces, quantitative  |
| 0431T | Removal and replacement of neurostimulator system for treatment of central sleep apnea, pulse generator only   |
| 0431U | Glycine receptor alpha1 IgG, serum or cerebrospinal fluid (CSF), live cell-binding assay (LCBA), qualitative   |
| 0432T | Repositioning of neurostimulator system for treatment of central sleep apnea; stimulation lead only  |
| 0432U | Kelch-like protein 11 (KLHL11) antibody, serum or cerebrospinal fluid (CSF), cell-binding assay, qualitative   |
| 0433T | Repositioning of neurostimulator system for treatment of central sleep apnea; sensing lead only  |
| 0434T | Interrogation device evaluation implanted neurostimulator pulse generator system for central sleep apnea   |
| 0435T | Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; single session  |
| 0435U | Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on cytotoxicity percentage observed, minimum of 14 drugs or drug combinations |
| 0436T | Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; during sleep study  |
| 0436U | Oncology (lung), plasma analysis of 388 proteins, using aptamerbased proteomics technology, predictive algorithm reported as clinical benefit from immune checkpoint inhibitor therapy   |
| 0437T | Implantation of non-biologic or synthetic implant (eg, polypropylene) for fascial reinforcement of the abdominal wall (List separately in addition to code for primary procedure)  |
| 0439T | Myocardial contrast perfusion echocardiography, at rest or with stress, for assessment of myocardial ischemia or viability (List separately in addition to code for primary procedure)   |
| 0440T | Ablation, percutaneous, cryoablation, includes imaging guidance; upper extremity distal/peripheral nerve   |
| 0441T | Ablation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve   |
| 0442T | Ablation, percutaneous, cryoablation, includes imaging guidance; nerve plexus or other truncal nerve (eg, brachial plexus, pudendal nerve)   |
| 0443T | Real-time spectral analysis of prostate tissue by fluorescence spectroscopy, including imaging guidance (List separately in addition to code for primary procedure)  |



|       |   |
|-------|---|
| 0444T | Initial placement of a drug-eluting ocular insert under one or more eyelids, including fitting, training, and insertion, unilateral or bilateral  |
| 0445T | Subsequent placement of a drug-eluting ocular insert under one or more eyelids, including re-training, and removal of existing insert, unilateral or bilateral  |
| 0446T | Creation of subcutaneous pocket with insertion of implantable interstitial glucose sensor, including system activation and patient training   |
| 0447T | Removal of implantable interstitial glucose sensor from subcutaneous pocket via incision  |
| 0448T | Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new implantable sensor, including system activation   |
| 0464T | Visual evoked potential, testing for glaucoma, with interpretation and report   |
| 0465T | Suprachoroidal injection of a pharmacologic agent (does not include supply of medication)   |
| 0469T | Retinal polarization scan, ocular screening with on-site automated results, bilateral   |
| 0472T | Device evaluation, interrogation, and initial programming of intra-ocular retinal electrode array (eg, retinal prosthesis), in person, with iterative adjustment of the implantable device to test functionality, select optimal permanent programmed values with analysis, including visual training, with review and report by a qualified health care professional |
| 0473T | Device evaluation and interrogation of intra-ocular retinal electrode array (eg, retinal prosthesis), in person, including reprogramming and visual training, when performed, with review and report by a qualified health care professional  |
| 0474T | Insertion of anterior segment aqueous drainage device, with creation of intraocular reservoir, internal approach, into the supraciliary space   |
| 0481T | Injection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed   |
| 0483T | Transcatheter mitral valve implantation/replacement (TMVI) with prosthetic valve; percutaneous approach, including transseptal puncture, when performed   |
| 0484T | Transcatheter mitral valve implantation/replacement (TMVI) with prosthetic valve; transthoracic exposure (eg, thoracotomy, transapical)   |
| 0485T | Optical coherence tomography (OCT) of middle ear, with interpretation and report; unilateral  |
| 0486T | Optical coherence tomography (OCT) of middle ear, with interpretation and report; bilateral   |
| 0489T | Autologous adipose-derived regenerative cell therapy for scleroderma in the hands; adipose tissue harvesting, isolation and preparation of harvested cells including incubation with cell dissociation enzymes, removal of non-viable cells and debris, determination of concentration and dilution of regenerative cells   |
| 0490T | Autologous adipose-derived regenerative cell therapy for scleroderma in the hands; multiple injections in one or both hands   |





|       |   |
|-------|---|
| 0494T | Surgical preparation and cannulation of marginal (extended) cadaver donor lung(s) to ex vivo organ perfusion system, including decannulation, separation from the perfusion system, and cold preservation of the allograft prior to implantation, when perform  |
| 0495T | Initiation and monitoring marginal (extended) cadaver donor lung(s) organ perfusion system by physician or qualified health care professional, including physiological and laboratory assessment (eg, pulmonary artery flow, pulmonary artery pressure, left atrial pressure, pulmonary vascular resistance, mean/peak and plateau airway pressure, dynamic compliance and perfusate gas analysis), including bronchoscopy and X ray when performed; first two hours in sterile field   |
| 0496T | Initiation and monitoring marginal (extended) cadaver donor lung(s) organ perfusion system by physician or qualified health care professional, including physiological and laboratory assessment (eg, pulmonary artery flow, pulmonary artery pressure, left atrial pressure, pulmonary vascular resistance, mean/peak and plateau airway pressure, dynamic compliance and perfusate gas analysis), including bronchoscopy and X ray when performed; each additional hour (List separately in addition to code for primary procedure) |
| 0499T | Cystourethroscopy, with mechanical dilation and urethral therapeutic drug delivery for urethral stricture or stenosis, including fluoroscopy, when performed  |
| 0500T | Infectious agent detection by nucleic acid (DNA or RNA), human papillomavirus (HPV) for five or more separately reported high-risk HPV types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) (ie, genotyping)  |
| 0505T | Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion             |
| 0506T | Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report  |
| 0507T | Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report   |
| 0508T | Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia  |
| 0509T | Electroretinography (ERG) with interpretation and report, pattern (PERG)  |
| 0510T | Removal of sinus tarsi implant  |
| 0511T | Removal and reinsertion of sinus tarsi implant  |
| 0512T | Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; initial wound SpaceOAR   |



|       |  |
|-------|--|
| 0513T | Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound (List separately in addition to code for primary procedure)<br>SpaceOAR   |
| 0515T | Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])   |
| 0516T | Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only   |
| 0517T | Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only   |
| 0518T | Removal of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacing   |
| 0519T | Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter)  |
| 0520T | Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode  |
| 0521T | Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing   |
| 0522T | Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing  |
| 0523T | Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention (List separately in addition to code for primary procedure) |
| 0524T | Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring   |
| 0525T | Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)  |
| 0526T | Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only   |



|       |   |
|-------|---|
| 0527T | Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only  |
| 0528T | Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report  |
| 0529T | Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report  |
| 0530T | Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)   |
| 0531T | Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only  |
| 0532T | Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only  |
| 0533T | Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review   |
| 0534T | Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set-up, patient training, configuration of monitor   |
| 0535T | Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration   |
| 0536T | Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report   |
| 0541T | Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learning-derived clinical scoring, and automated report generation, single study;                           |
| 0542T | Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learning-derived clinical scoring, and automated report generation, single study; interpretation and report |
| 0543T | Transapical mitral valve repair, including transthoracic echocardiography, when performed, with placement of artificial chordae tendineae   |
| 0544T | Transcatheter mitral valve annulus reconstruction, with implantation of adjustable annulus reconstruction device, percutaneous approach including transseptal puncture  |



|       |  |
|-------|--|
| 0545T | Transcatheter tricuspid valve annulus reconstruction with implantation of adjustable annulus reconstruction device, percutaneous approach  |
| 0546T | Radiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of partial mastectomy, with report   |
| 0547T | Bone-material quality testing by microindentation(s) of the tibia(s), with results reported as a score   |
| 0552T | Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional  |
| 0553T | Percutaneous transcatheter placement of iliac arteriovenous anastomosis implant, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention  |
| 0554T | Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; retrieval and transmission of the scan data, assessment of bone strength and fracture risk and bone mineral density, interpretation and report |
| 0555T | retrieval and transmission of the scan data  |
| 0556T | assessment of bone strength and fracture risk and bone mineral density   |
| 0557T | interpretation and report  |
| 0558T | Computed tomography scan taken for the purpose of biomechanical computed tomography analysis   |
| 0559T | Anatomic model 3D-printed from image data set(s); first individually prepared and processed component of an anatomic structure   |
| 0560T | each additional individually prepared and processed component of an anatomic structure (List separately in addition to code for primary procedure)   |
| 0561T | Anatomic guide 3D-printed and designed from image data set(s); first anatomic guide  |
| 0562T | each additional anatomic guide (List separately in addition to code for primary procedure)   |
| 0563T | Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral  |
| 0564T | Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on percent of cytotoxicity observed, a minimum of 14 drugs or drug combinations   |
| 0565T | Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation  |
| 0566T | Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral  |
| 0567T | Permanent fallopian tube occlusion with degradable biopolymer implant, transcervical approach, including transvaginal ultrasound   |



|       |   |
|-------|---|
| 0568T | Introduction of mixture of saline and air for sonosalpingography to confirm occlusion of fallopian tubes, transcervical approach, including transvaginal ultrasound and pelvic ultrasound   |
| 0569T | Transcatheter tricuspid valve repair, percutaneous approach; initial prosthesis   |
| 0570T | Transcatheter tricuspid valve repair, percutaneous approach; each additional prosthesis during same session (List separately in addition to code for primary procedure)   |
| 0571T | Insertion or replacement of implantable cardioverter-defibrillator system with substernal electrode(s), including all imaging guidance and electrophysiological evaluation (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters), when performed |
| 0572T | Insertion of substernal implantable defibrillator electrode   |
| 0573T | Removal of substernal implantable defibrillator electrode   |
| 0574T | Repositioning of previously implanted substernal implantable defibrillator-pacing electrode   |
| 0575T | Programming device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional                                     |
| 0576T | Interrogation device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter   |
| 0577T | Electrophysiological evaluation of implantable cardioverter-defibrillator system with substernal electrode (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters)   |
| 0578T | Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional   |
| 0579T | Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results  |
| 0580T | Removal of substernal implantable defibrillator pulse generator only  |
| 0581T | Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral   |
| 0582T | Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance  |
| 0583T | Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia   |



|       |   |
|-------|---|
| 0584T | Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; percutaneous  |
| 0585T | Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; laparoscopic  |
| 0586T | Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; open  |
| 0587T | Percutaneous implantation or replacement of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve  |
| 0588T | Revision or removal of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve   |
| 0589T | Electronic analysis with simple programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters        |
| 0590T | Electronic analysis with complex programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters |
| 0591T | Health and well-being coaching face-to-face; individual, initial assessment   |
| 0592T | Health and well-being coaching face-to-face; individual, follow-up session, at least 30 minutes   |
| 0593T | Health and well-being coaching face-to-face; group (2 or more individuals), at least 30 minutes   |
| 0594T | Osteotomy, humerus, with insertion of an externally controlled intramedullary lengthening device, including intraoperative imaging, initial and subsequent alignment assessments, computations of adjustment schedules, and management of the intramedullary lengthening device   |
| 0596T | Temporary female intraurethral valve-pump (ie, voiding prosthesis); initial insertion, including urethral measurement   |
| 0597T | Temporary female intraurethral valve-pump (ie, voiding prosthesis); replacement   |



|       |  |
|-------|--|
| 0598T | Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; first anatomic site (eg, lower extremity)  |
| 0599T | Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; each additional anatomic site (eg, upper extremity) (List separately in addition to code for primary procedure)  |
| 0600T | Ablation, irreversible electroporation; 1 or more tumors per organ, including imaging guidance, when performed, percutaneous   |
| 0601T | Ablation, irreversible electroporation; 1 or more tumors, including fluoroscopic and ultrasound guidance, when performed, open   |
| 0602T | Glomerular filtration rate (GFR) measurement(s), transdermal, including sensor placement and administration of a single dose of fluorescent pyrazine agent   |
| 0603T | Glomerular filtration rate (GFR) monitoring, transdermal, including sensor placement and administration of more than one dose of fluorescent pyrazine agent, each 24 hours   |
| 0604T | Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; initial device provision, set-up and patient education on use of equipment   |
| 0605T | Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; remote surveillance center technical support, data analyses and reports, with a minimum of 8 daily recordings, each 30 days  |
| 0606T | Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; review, interpretation and report by the prescribing physician or other qualified health care professional of remote surveillance center data analyses, each 30 days   |
| 0607T | Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; set-up and patient education on use of equipment   |
| 0608T | Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; analysis of data received and transmission of reports to the physician or other qualified health care professional |
| 0613T | Percutaneous transcatheter implantation of interatrial septal shunt device, including right and left heart catheterization, intracardiac echocardiography, and imaging guidance by the proceduralist, when performed   |
| 0614T | Removal and replacement of substernal implantable defibrillator pulse generator  |
| 0615T | Eye-movement analysis without spatial calibration, with interpretation and report  |



|                  |  |
|------------------|--|
| 0616T            | Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; without removal of crystalline lens or intraocular lens, without insertion of intraocular lens  |
| 0617T            | Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; with removal of crystalline lens and insertion of intraocular lens  |
| 0618T            | Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; with secondary intraocular lens placement or intraocular lens exchange  |
| 0619T            | Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed  |
| 0620T            | Endovascular venous arterialization, tibial or peroneal vein, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed |
| 0621T            | Trabeculectomy ab interno by laser   |
| 0622T            | Trabeculectomy ab interno by laser; with use of ophthalmic endoscope   |
| 0623T            | Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, computerized analysis of data, with review of computerized analysis output to reconcile discordant data, interpretation and report  |
| 0624 (Rev Code ) | FDA Investigational Device (Rev Code)  |
| 0624T            | Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission  |
| 0625T            | Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; computerized analysis of data from coronary computed tomographic angiography   |
| 0626T            | Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; review of computerized analysis output to reconcile discordant data, interpretation and report   |
| 0627T            | Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level   |
| 0628T            | Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure)   |





|       |   |
|-------|---|
| 0629T | Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level  |
| 0630T | Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure)                |
| 0631T | Transcutaneous visible light hyperspectral imaging measurement of oxyhemoglobin, deoxyhemoglobin, and tissue oxygenation, with interpretation and report, per extremity   |
| 0632T | Percutaneous transcatheter ultrasound ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance  |
| 0639T | Wireless skin sensor thermal anisotropy measurement(s) and assessment of flow in cerebrospinal fluid shunt, including ultrasound guidance, when performed   |
| 0640T | Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); image acquisition, interpretation and report, each flap or wound                              |
| 0641T | Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); image acquisition only, each flap or wound  |
| 0642T | Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); interpretation and report only, each flap or wound  |
| 0643T | Transcatheter left ventricular restoration device implantation including right and left heart catheterization and left ventriculography when performed, arterial approach   |
| 0644T | Transcatheter removal or debulking of intracardiac mass (eg, vegetations, thrombus) via suction (eg, vacuum, aspiration) device, percutaneous approach, with intraoperative reinfusion of aspirated blood, including imaging guidance, when performed         |
| 0645T | Transcatheter implantation of coronary sinus reduction device including vascular access and closure, right heart catheterization, venous angiography, coronary sinus angiography, imaging guidance, and supervision and interpretation, when performed        |
| 0646T | Transcatheter tricuspid valve implantation/replacement (TTVI) with prosthetic valve, percutaneous approach, including right heart catheterization, temporary pacemaker insertion, and selective right ventricular or right atrial angiography, when performed |
| 0647T | Insertion of gastrostomy tube, percutaneous, with magnetic gastropexy, under ultrasound guidance, image documentation and report  |
| 0648T | Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without                                 |



|       |  |
|-------|--|
|       | diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session  |
| 0649T | Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure) |
| 0650T | Programming device evaluation (remote) of subcutaneous cardiac rhythm monitor system, with iterative adjustment of the implantable device to test the function of the device and select optimal permanently programmed values with analysis, review and report by a physician or other qualified health care professional  |
| 0651T | Magnetically controlled capsule endoscopy, esophagus through stomach, including intraprocedural positioning of capsule, with interpretation and report   |
| 0652T | Esophagogastroduodenoscopy, flexible, transnasal; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)  |
| 0653T | Esophagogastroduodenoscopy, flexible, transnasal; with biopsy, single or multiple  |
| 0654T | Esophagogastroduodenoscopy, flexible, transnasal; with insertion of intraluminal tube or catheter  |
| 0655T | Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging   |
| 0658T | Electrical impedance spectroscopy of 1 or more skin lesions for automated melanoma risk score  |
| 0659T | Transcatheter intracoronary infusion of supersaturated oxygen in conjunction with percutaneous coronary revascularization during acute myocardial infarction, including catheter placement, imaging guidance (eg, fluoroscopy), angiography, and radiologic supervision and interpretation   |
| 0660T | Implantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach   |
| 0661T | Removal and reimplantation of anterior segment intraocular nonbiodegradable drug-eluting implant   |
| 0664T | Donor hysterectomy (including cold preservation); open, from cadaver donor   |
| 0665T | Donor hysterectomy (including cold preservation); open, from living donor  |
| 0666T | Donor hysterectomy (including cold preservation); laparoscopic or robotic, from living donor   |
| 0667T | Donor hysterectomy (including cold preservation); recipient uterus allograft transplantation from cadaver or living donor  |
| 0668T | Backbench standard preparation of cadaver or living donor uterine allograft prior to transplantation, including dissection and removal of surrounding soft tissues and preparation of uterine vein(s) and uterine artery(ies), as necessary  |



|       |  |
|-------|--|
| 0669T | Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; venous anastomosis, each  |
| 0670T | Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; arterial anastomosis, each  |
| 0671T | Insertion of anterior segment aqueous drainage device into the trabecular meshwork, without external reservoir, and without concomitant cataract removal, one or more  |
| 0672T | Endovaginal cryogen-cooled, monopolar radiofrequency remodeling of the tissues surrounding the female bladder neck and proximal urethra for urinary incontinence   |
| 0673T | Ablation, benign thyroid nodule(s), percutaneous, laser, including imaging guidance  |
| 0674T | Laparoscopic insertion of new or replacement of permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including an implantable pulse generator and diaphragmatic lead(s)   |
| 0675T | Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first lead   |
| 0676T | Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional lead (List separately in addition to code for primary procedure) |
| 0677T | Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first repositioned lead  |
| 0678T | Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional repositioned lead (List separately in addition to code for primary procedure)      |
| 0679T | Laparoscopic removal of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function  |
| 0680T | Insertion or replacement of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing lead(s)  |
| 0681T | Relocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads   |
| 0682T | Removal of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function  |



|       |   |
|-------|---|
| 0683T | Programming device evaluation (in-person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function |
| 0684T | Peri-procedural device evaluation (in-person) and programming of device system parameters before or after a surgery, procedure, or test with analysis, review, and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function  |
| 0685T | Interrogation device evaluation (in-person) with analysis, review and report by a physician or other qualified health care professional, including connection, recording and disconnection per patient encounter, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function  |
| 0686T | Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant hepatocellular tissue, including image guidance  |
| 0687T | Treatment of amblyopia using an online digital program; device supply, educational set-up, and initial session  |
| 0688T | Treatment of amblyopia using an online digital program; assessment of patient performance and program data by physician or other qualified health care professional, with report, per calendar month  |
| 0689T | Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained without diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure)   |
| 0690T | Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained with diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure)  |
| 0691T | Automated analysis of an existing computed tomography study for vertebral fracture(s), including assessment of bone density when performed, data preparation, interpretation, and report  |
| 0692T | Therapeutic ultrafiltration   |
| 0693T | Comprehensive full body computer-based markerless 3D kinematic and kinetic motion analysis and report   |
| 0694T | 3-dimensional volumetric imaging and reconstruction of breast or axillary lymph node tissue, each excised specimen, 3-dimensional automatic specimen reorientation, interpretation and report, real-time intraoperative   |
| 0695T | Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of implant or replacement   |



|       |   |
|-------|---|
| 0696T | Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of follow-up interrogation or programming device evaluation   |
| 0697T | Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session; multiple organs                                  |
| 0698T | Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure); multiple organs (List separately in addition to code for primary procedure) |
| 0699T | Injection, posterior chamber of eye, medication   |
| 0700T | Molecular fluorescent imaging of suspicious nevus; first lesion   |
| 0701T | Molecular fluorescent imaging of suspicious nevus; each additional lesion (List separately in addition to code for primary procedure)   |
| 0704T | Remote treatment of amblyopia using an eye tracking device; device supply with initial set-up and patient education on use of equipment   |
| 0705T | Remote treatment of amblyopia using an eye tracking device; surveillance center technical support including data transmission with analysis, with a minimum of 18 training hours, each 30 days  |
| 0706T | Remote treatment of amblyopia using an eye tracking device; interpretation and report by physician or other qualified health care professional, per calendar month  |
| 0707T | Injection(s), bone-substitute material (eg, calcium phosphate) into subchondral bone defect (ie, bone marrow lesion, bone bruise, stress injury, microtrabecular fracture), including imaging guidance and arthroscopic assistance for joint visualization  |
| 0708T | Intradermal cancer immunotherapy; preparation and initial injection   |
| 0709T | Intradermal cancer immunotherapy; each additional injection (List separately in addition to code for primary procedure)   |
| 0710T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; including data preparation and transmission, quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability, data review, interpretation and report                 |
| 0711T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data preparation and transmission   |
| 0712T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; quantification of the   |



|       |   |
|-------|---|
|       | structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability  |
| 0713T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data review, interpretation and report  |
| 0714T | Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance  |
| 0715T | Percutaneous transluminal coronary lithotripsy (List separately in addition to code for primary procedure)  |
| 0716T | Cardiac acoustic waveform recording with automated analysis and generation of coronary artery disease risk score  |
| 0717T | Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; adipose tissue harvesting, isolation and preparation of harvested cells, including incubation with cell dissociation enzymes, filtration, washing and concentration of ADRCs   |
| 0718T | Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; injection into supraspinatus tendon including ultrasound guidance, unilateral  |
| 0719T | Posterior vertebral joint replacement, including bilateral facetectomy, laminectomy, and radical discectomy, including imaging guidance, lumbar spine, single segment   |
| 0720T | Percutaneous electrical nerve field stimulation, cranial nerves, without implantation   |
| 0721T | Quantitative computed tomography (CT) tissue characterization, including interpretation and report, obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging   |
| 0722T | Quantitative computed tomography (CT) tissue characterization, including interpretation and report, obtained with concurrent CT examination of any structure contained in the concurrently acquired diagnostic imaging dataset (List separately in addition to code for primary procedure)  |
| 0723T | Quantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained without diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session                                  |
| 0724T | Quantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained with diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure) |
| 0725T | Vestibular device implantation, unilateral  |
| 0726T | Removal of implanted vestibular device, unilateral  |
| 0727T | Removal and replacement of implanted vestibular device, unilateral  |
| 0728T | Diagnostic analysis of vestibular implant, unilateral; with initial programming   |



|       |  |
|-------|--|
| 0729T | Diagnostic analysis of vestibular implant, unilateral; with subsequent programming   |
| 0730T | Trabeculotomy by laser, including optical coherence tomography (OCT) guidance  |
| 0731T | Augmentative AI-based facial phenotype analysis with report  |
| 0732T | Immunotherapy administration with electroporation, intramuscular   |
| 0733T | Remote body and limb kinematic measurement-based therapy ordered by a physician or other qualified health care professional; supply and technical support, per 30 days   |
| 0734T | Remote body and limb kinematic measurement-based therapy ordered by a physician or other qualified health care professional; treatment management services by a physician or other qualified health care professional, per calendar month  |
| 0735T | Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with primary craniotomy (List separately in addition to code for primary procedure)   |
| 0736T | Colonic lavage, 35 or more liters of water, gravity-fed, with induced defecation, including insertion of rectal catheter   |
| 0737T | Xenograft implantation into the articular surface  |
| 0738T | Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination   |
| 0739T | Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation  |
| 0740T | Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration; initial set-up and patient education   |
| 0741T | Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration; provision of software, data collection, transmission, and storage, each 30 days  |
| 0742T | Absolute quantitation of myocardial blood flow (AQMBF), single-photon emission computed tomography (SPECT), with exercise or pharmacologic stress, and at rest, when performed (List separately in addition to code for primary procedure)   |
| 0743T | Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density, with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan, retrieval and transmission of the scan data, measurement of bone strength and bone mineral density and classification of any vertebral fractures, with overall fracture risk assessment, interpretation and report |
| 0744T | Insertion of bioprosthetic valve, open, femoral vein, including duplex ultrasound imaging guidance, when performed, including autogenous or nonautogenous patch graft (eg, polyester, ePTFE, bovine pericardium), when performed   |



|       |  |
|-------|--|
| 0745T | Cardiac focal ablation utilizing radiation therapy for arrhythmia; noninvasive arrhythmia localization and mapping of arrhythmia site (nidus), derived from anatomical image data (eg, CT, MRI, or myocardial perfusion scan) and electrical data (eg, 12-lead ECG data), and identification of areas of avoidance   |
| 0746T | Cardiac focal ablation utilizing radiation therapy for arrhythmia; conversion of arrhythmia localization and mapping of arrhythmia site (nidus) into a multidimensional radiation treatment plan   |
| 0747T | Cardiac focal ablation utilizing radiation therapy for arrhythmia; delivery of radiation therapy, arrhythmia   |
| 0748T | Injections of stem cell product into perianal perirectal soft tissue, including fistula preparation (eg, removal of setons, fistula curettage, closure of internal openings)   |
| 0749T | Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk and BMD, interpretation and report;   |
| 0750T | Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk and BMD, interpretation and report; with single-view digital X-ray examination of the hand taken for the purpose of DXR-BMD |
| 0751T | Digitization of glass microscope slides for level II, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)  |
| 0752T | Digitization of glass microscope slides for level III, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)   |
| 0753T | Digitization of glass microscope slides for level IV, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)  |
| 0754T | Digitization of glass microscope slides for level V, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)   |
| 0755T | Digitization of glass microscope slide for level VI, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)   |
| 0756T | Digitization of glass microscope slides for special stain, including interpretation and report, group I, for microorganisms (eg, acid fast, methenamine silver) (List separately in addition to code for primary procedure)  |
| 0757T | Digitization of glass microscope slides for special stain, including interpretation and report, group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and   |





|       |   |
|-------|---|
|       | immunohistochemistry (List separately in addition to code for primary procedure)  |
| 0758T | Digitization of glass microscope slides for special stain, including interpretation and report, histochemical stain on frozen tissue block (List separately in addition to code for primary procedure)  |
| 0759T | Digitization of glass microscope slides for special stain, including interpretation and report, group III, for enzyme constituents (List separately in addition to code for primary procedure)  |
| 0760T | Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, initial single antibody stain procedure (List separately in addition to code for primary procedure)  |
| 0761T | Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each additional single antibody stain procedure (List separately in addition to code for primary procedure)  |
| 0762T | Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each multiplex antibody stain procedure (List separately in addition to code for primary procedure)  |
| 0763T | Digitization of glass microscope slides for morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure, manual (List separately in addition to code for primary procedure)  |
| 0764T | Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to concurrently performed electrocardiogram (List separately in addition to code for primary procedure)   |
| 0765T | Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to previously performed electrocardiogram   |
| 0766T | Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, initial treatment, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve   |
| 0767T | Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, initial treatment, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve (List separately in addition to code for primary procedure) |
| 0768T | Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, subsequent treatment, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve   |



|       |   |
|-------|---|
| 0769T | Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, subsequent treatment, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve (List separately in addition to code for primary procedure)   |
| 0770T | Virtual reality technology to assist therapy (List separately in addition to code for primary procedure)  |
| 0771T | Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older                                  |
| 0772T | Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; each additional 15 minutes intraservice time (List separately in addition to code for primary service) |
| 0773T | Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; initial 15 minutes of intraservice time, patient age 5 years or older   |
| 0774T | Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; each additional 15 minutes intraservice time (List separately in addition to code for primary service)  |
| 0775T | Arthrodesis, sacroiliac joint, percutaneous, with image guidance, includes placement of intra-articular implant(s) (eg, bone allograft[s], synthetic device[s])   |
| 0776T | Therapeutic induction of intra-brain hypothermia, including placement of a mechanical temperature-controlled cooling device to the neck over carotids and head, including monitoring (eg, vital signs and sport concussion assessment tool 5 [SCAT5]), 30 minutes of treatment  |
| 0777T | Real-time pressure-sensing epidural guidance system (List separately in addition to code for primary procedure)   |
| 0778T | Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle function   |
| 0779T | Gastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report  |



|       |  |
|-------|--|
| 0780T | Instillation of fecal microbiota suspension via rectal enema into lower gastrointestinal tract   |
| 0781T | Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; bilateral mainstem bronchi   |
| 0782T | Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; unilateral mainstem bronchus   |
| 0783T | Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment  |
| 0784T | Insertion or replacement of percutaneous electrode array, spinal, with integrated neurostimulator, including imaging guidance, when performed  |
| 0785T | Revision or removal of neurostimulator electrode array, spinal, with integrated neurostimulator  |
| 0786T | Insertion or replacement of percutaneous electrode array, sacral, with integrated neurostimulator, including imaging guidance, when performed  |
| 0787T | Revision or removal of neurostimulator electrode array, sacral, with integrated neurostimulator  |
| 0788T | Electronic analysis with simple programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, spinal cord or sacral nerve, 1-3 parameters        |
| 0789T | Electronic analysis with complex programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, spinal cord or sacral nerve, 4 or more parameters |
| 0791T | Motor-cognitive, semi-immersive virtual reality-facilitated gait training, each 15 minutes (List separately in addition to code for primary procedure)   |
| 0792T | Application of silver diamine fluoride 38%, by a physician or other qualified health care professional   |
| 0793T | Percutaneous transcatheter thermal ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance  |
| 0794T | Patient-specific, assistive, rules-based algorithm for ranking pharmacologic treatment options based on the patient's tumor-specific cancer marker information obtained from prior molecular pathology, immunohistochemical, or other pathology results which have been previously interpreted and reported separately   |



|       |   |
|-------|---|
| 0795T | Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; complete system (ie, right atrial and right ventricular pacemaker components)   |
| 0796T | Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right atrial pacemaker component (when an existing right ventricular single leadless pacemaker exists to create a dual-chamber leadless pacemaker system) |
| 0797T | Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)   |
| 0798T | Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; complete system (ie, right atrial and right ventricular pacemaker components)  |
| 0799T | Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right atrial pacemaker component   |
| 0800T | Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)  |
| 0801T | Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; dual-chamber system (ie, right atrial and right ventricular pacemaker components)   |
| 0802T | Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right atrial pacemaker component  |
| 0803T | Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right   |



|       |  |
|-------|--|
|       | ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)  |
| 0804T | Programming device evaluation (in person) with iterative adjustment of implantable device to test the function of device and to select optimal permanent programmed values, with analysis, review, and report, by a physician or other qualified health care professional, leadless pacemaker system in dual cardiac chambers  |
| 0805T | Transcatheter superior and inferior vena cava prosthetic valve implantation (ie, caval valve implantation [CAVI]); percutaneous femoral vein approach  |
| 0806T | Transcatheter superior and inferior vena cava prosthetic valve implantation (ie, caval valve implantation [CAVI]); open femoral vein approach  |
| 0807T | Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with previously acquired computed tomography (CT) images, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report  |
| 0808T | Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with computed tomography (CT) images taken for the purpose of pulmonary tissue ventilation analysis, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report |
| 0809T | Arthrodesis, sacroiliac joint, percutaneous or minimally invasive (indirect visualization), with image guidance, placement of transfixing device(s) and intra-articular implant(s), including allograft or synthetic device(s)   |
| 0810T | Subretinal injection of a pharmacologic agent, including vitrectomy and 1 or more retinotomies   |
| 0811T | Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment); set-up and patient education on use of equipment  |
| 0812T | Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment); device supply with automated report generation, up to 10 days   |
| 0813T | Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon  |
| 0814T | Percutaneous injection of calcium-based biodegradable osteoconductive material, proximal femur, including imaging guidance, unilateral   |
| 0815T | Ultrasound-based radiofrequency echographic multi-spectrometry (REMS), bone-density study and fracture-risk assessment, 1 or more sites, hips, pelvis, or spine  |
| 0816T | Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subcutaneous   |
| 0817T | Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse  |



|       |  |
|-------|--|
|       | generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subfascial   |
| 0818T | Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve; subcutaneous  |
| 0819T | Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve; subfascial  |
| 0820T | Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other qualified health care professional, each hour  |
| 0821T | Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; second physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure)                                  |
| 0822T | Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; clinical staff under the direction of a physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure) |
| 0823T | Transcatheter insertion of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography) and device evaluation (eg, interrogation or programming), when performed   |
| 0824T | Transcatheter removal of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography), when performed  |
| 0825T | Transcatheter removal and replacement of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography) and device evaluation (eg, interrogation or programming), when performed   |
| 0826T | Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional, leadless pacemaker system in single-cardiac chamber   |
| 0827T | Digitization of glass microscope slides for cytopathology, fluids, washings, or brushings, except cervical or vaginal; smears with interpretation (List separately in addition to code for primary procedure)  |



|       |   |
|-------|---|
| 0828T | Digitization of glass microscope slides for cytopathology, fluids, washings, or brushings, except cervical or vaginal; simple filter method with interpretation (List separately in addition to code for primary procedure)   |
| 0829T | Digitization of glass microscope slides for cytopathology, concentration technique, smears, and interpretation (eg, Saccomanno technique) (List separately in addition to code for primary procedure)   |
| 0830T | Digitization of glass microscope slides for cytopathology, selective-cellular enhancement technique with interpretation (eg, liquid-based slide preparation method), except cervical or vaginal (List separately in addition to code for primary procedure)                           |
| 0831T | Digitization of glass microscope slides for cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician (List separately in addition to code for primary procedure)  |
| 0832T | Digitization of glass microscope slides for cytopathology, smears, any other source; screening and interpretation (List separately in addition to code for primary procedure)   |
| 0833T | Digitization of glass microscope slides for cytopathology, smears, any other source; preparation, screening and interpretation (List separately in addition to code for primary procedure)  |
| 0834T | Digitization of glass microscope slides for cytopathology, smears, any other source; extended study involving over 5 slides and/or multiple stains (List separately in addition to code for primary procedure)  |
| 0835T | Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site (List separately in addition to code for primary procedure)                    |
| 0836T | Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, each separate additional evaluation episode, same site (List separately in addition to code for primary procedure) |
| 0837T | Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; interpretation and report (List separately in addition to code for primary procedure)  |
| 0838T | Digitization of glass microscope slides for consultation and report on referred slides prepared elsewhere (List separately in addition to code for primary procedure)   |
| 0839T | Digitization of glass microscope slides for consultation and report on referred material requiring preparation of slides (List separately in addition to code for primary procedure)  |
| 0840T | Digitization of glass microscope slides for consultation, comprehensive, with review of records and specimens, with report on referred material (List separately in addition to code for primary procedure)   |
| 0841T | Digitization of glass microscope slides for pathology consultation during surgery; first tissue block, with frozen section(s), single specimen (List separately in addition to code for primary procedure)  |



|       |   |
|-------|---|
| 0842T | Digitization of glass microscope slides for pathology consultation during surgery; each additional tissue block with frozen section(s) (List separately in addition to code for primary procedure)  |
| 0843T | Digitization of glass microscope slides for pathology consultation during surgery; cytologic examination (eg, touch preparation, squash preparation), initial site (List separately in addition to code for primary procedure)                              |
| 0844T | Digitization of glass microscope slides for pathology consultation during surgery; cytologic examination (eg, touch preparation, squash preparation), each additional site (List separately in addition to code for primary procedure)                      |
| 0845T | Digitization of glass microscope slides for immunofluorescence, per specimen; initial single antibody stain procedure (List separately in addition to code for primary procedure)   |
| 0846T | Digitization of glass microscope slides for immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)   |
| 0847T | Digitization of glass microscope slides for examination and selection of retrieved archival (ie, previously diagnosed) tissue(s) for molecular analysis (eg, KRAS mutational analysis) (List separately in addition to code for primary procedure)          |
| 0848T | Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; initial single probe stain procedure (List separately in addition to code for primary procedure)  |
| 0849T | Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure)  |
| 0850T | Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; each multiplex probe stain procedure (List separately in addition to code for primary procedure)  |
| 0851T | Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; initial single probe stain procedure (List separately in addition to code for primary procedure)         |
| 0852T | Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure) |
| 0853T | Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; each multiplex probe stain procedure (List separately in addition to code for primary procedure)         |
| 0854T | Digitization of glass microscope slides for blood smear, peripheral, interpretation by physician with written report (List separately in addition to code for primary procedure)  |
| 0855T | Digitization of glass microscope slides for bone marrow, smear interpretation (List separately in addition to code for primary procedure)   |





|       |   |
|-------|---|
| 0856T | Digitization of glass microscope slides for electron microscopy, diagnostic (List separately in addition to code for primary procedure)   |
| 0857T | Opto-acoustic imaging, breast, unilateral, including axilla when performed, real-time with image documentation, augmentative analysis and report (List separately in addition to code for primary procedure)  |
| 0858T | Externally applied transcranial magnetic stimulation with concomitant measurement of evoked cortical potentials with automated report   |
| 0859T | Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), other than for screening for peripheral arterial disease, image acquisition, interpretation, and report; each additional anatomic site (List separately in addition to code for primary procedure)  |
| 0860T | Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), for screening for peripheral arterial disease, including provocative maneuvers, image acquisition, interpretation, and report, one or both lower extremities  |
| 0861T | Removal of pulse generator for wireless cardiac stimulator for left ventricular pacing; both components (battery and transmitter)   |
| 0862T | Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; battery component only   |
| 0863T | Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; transmitter component only   |
| 0864T | Low-intensity extracorporeal shock wave therapy involving corpus cavernosum, low energy   |
| 0865T | Quantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion identification, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the brain during the same session                             |
| 0866T | Quantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion detection, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the brain (List separately in addition to code for primary procedure) |
| A2001 | Innovamatrix ac, per square centimeter  |
| A2002 | Mirragen advanced wound matrix, per square centimeter   |
| A2004 | Xcellstem, per square centimeter  |
| A2005 | Microlyte matrix, per square centimeter   |
| A2006 | Novosorb synpath dermal matrix, per square centimeter   |



|       |   |
|-------|---|
| A2007 | Restrata, per square centimeter   |
| A2008 | Theragenesis, per square centimeter   |
| A2009 | Symphony, per square centimeter   |
| A2010 | Apis, per square centimeter   |
| A2011 | Supra sdrm, per square centimeter   |
| A2012 | Suprathel, per square centimeter  |
| A2013 | Innovamatrix fs, per square centimeter  |
| A2014 | Omeza collagen matrix, per 100 mg   |
| A2015 | Phoenix wound matrix, per square centimeter   |
| A2016 | Permeaderm b, per square centimeter   |
| A2017 | Permeaderm glove, each  |
| A2018 | Permeaderm c, per square centimeter   |
| A2019 | Kerecis omega3 marigen shield, per square centimeter  |
| A2020 | Ac5 advanced wound system (ac5)   |
| A2021 | Neomatrix, per square centimeter  |
| A2022 | Innovaburn or innovamatrix xl, per square centimeter  |
| A2023 | Innovamatrix pd, 1 mg   |
| A2024 | Resolve matrix, per square centimeter   |
| A2025 | Miro3d, per cubic centimeter  |
| A2026 | Restrata minimatrix, 5 mg   |
| A2027 | Matriderm, per square centimeter  |
| A2028 | Micromatrix flex, per mg  |
| A4271 | Integrated lancing and blood sample testing cartridges for home blood glucose monitor, per month                              |
| A4438 | Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each                             |
| A4468 | Exsufflation belt, includes all supplies and accessories  |
| A4540 | Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm                              |
| A4541 | Monthly supplies for use of device coded at e0733   |
| A4542 | Supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist                      |
| A4544 | Electrode for external lower extremity nerve stimulator for restless legs syndrome  |
| A4560 | Neuromuscular electrical stimulator (nmes), disposable, replacement only  |
| A4563 | Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each |
| A4564 | Pessary, disposable, any type   |
| A4593 | Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, controller                                       |



|   |  |
|---|--|
| A4594   | Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece each   |
| A4596   | Cranial electrotherapy stimulation (ces) system supplies and accessories, per month            |
| A7049   | Expiratory positive airway pressure intranasal resistance valve                                |
| A9156   | Oral mucoadhesive, any type (liquid, gel, paste, etc.), per 1 ml                               |
| A9285   | Inversion/eversion correction device   |
| A9286   | Hygienic item or device, disposable or non-disposable, any type, each                          |
| A9292   | Prescription digital visual therapy, software-only, fda cleared, per course of treatment       |
| A9506   | Graphite crucible for preparation of technetium tc 99m-labeled carbon aerosol, one crucible    |
| A9591   | Fluoroestradiol f 18, diagnostic, 1 millicurie   |
| A9592   | Copper cu-64, dotatate, diagnostic, 1 millicurie   |
| A9601   | Flortaucipir f 18 injection, diagnostic, 1 millicurie  |
| A9602   | Fluorodopa f-18, diagnostic, per millicurie  |
| A9609   | Fludeoxyglucose f18 up to 15 millicuries   |
| Active release technique (ART) by Chiropractor                                    | Active release technique (ART) by Chiropractor   |
| Active Release Therapy  | Active Release Therapy (ART) is a type of massage therapy                                      |
| Acupressure   | Acupressure Energy medicine.   |
| Anser ADA, Anser IFX Lab Tests  | Anser ADA and Anser IFX lab tests, refreshed benchmarking and Hayes                            |
| AxioBionics Wearable Therapy Functional Neuromuscular Electrical Stimulation NMES | AxioBionics Wearable Therapy Functional Neuromuscular Electrical Stimulation NMES              |
| Bee Venom Therapy   | Bee Venom Therapy (BVT)  |
| BiowaveGO Neuromodulation Pain Therapy Device                                     | BiowaveGO Neuromodulation Pain Therapy Device  |
| C1052   | Hemostatic agent, gastrointestinal, topical  |
| C1062   | Intravertebral body fracture augmentation with implant (e.g., metal, polymer)                  |
| C1600   | Catheter, transluminal intravascular lesion preparation device, bladed, sheathed (insertable)  |
| C1601   | Endoscope, single-use (i.e. disposable), pulmonary, imaging/illumination device (insertable)   |
| C1602   | Orthopedic/device/drug matrix/absorbable bone void filler, antimicrobial-eluting (implantable) |
| C1603   | Retrieval device, insertable, laser (used to retrieve intravascular inferior vena cava filter) |



|       |  |
|-------|--|
| C1604 | Graft, transmural transvenous arterial bypass (implantable), with all delivery system components   |
| C1605 | Pacemaker, leadless, dual chamber (right atrial and right ventricular implantable components), rate-responsive, including all necessary components for implantation  |
| C1606 | Adapter, single-use (i.e. disposable), for attaching ultrasound system to upper gastrointestinal endoscope   |
| C1734 | Orthopedic/device/drug matrix for opposing bone-to-bone or soft tissue-to-bone (implantable)   |
| C1747 | Endoscope, single-use (i.e. disposable), urinary tract, imaging/illumination device (insertable)   |
| C1748 | Endoscope, single-use (i.e. disposable), upper gi, imaging/illumination device (insertable)  |
| C1761 | Catheter, transluminal intravascular lithotripsy, coronary   |
| C1821 | Interspinous process distraction device (implantable)  |
| C1824 | Generator, cardiac contractility modulation (implantable)  |
| C1825 | Generator, neurostimulator (implantable), non-rechargeable with carotid sinus baroreceptor stimulation lead(s)   |
| C1826 | Generator, neurostimulator (implantable), includes closed feedback loop leads and all implantable components, with rechargeable battery and charging system  |
| C1827 | Generator, neurostimulator (implantable), non-rechargeable, with implantable stimulation lead and external paired stimulation controller   |
| C1831 | Personalized, anterior and lateral interbody cage (implantable)  |
| C1832 | Autograft suspension, including cell processing and application, and all system components   |
| C1833 | Monitor, cardiac, including intracardiac lead and all system components (implantable)  |
| C1834 | Pressure sensor system, includes all components (e.g., introducer, sensor), intramuscular (implantable), excludes mobile (wireless) software application   |
| C1839 | Iris prosthesis  |
| C1884 | Embolization protective system   |
| C1982 | Catheter, pressure generating, one-way valve, intermittently occlusive   |
| C2613 | Lung Biopsy Plug with Delivery System  |
| C7557 | Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed and intraprocedural coronary fractional flow reserve (ffr) with 3d functional mapping of color-coded ffr values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention |
| C9089 | Bupivacaine, collagen-matrix implant, 1 mg   |



|       |   |
|-------|---|
| C9150 | Xenon xe-129 hyperpolarized gas, diagnostic, per study dose   |
| C9250 | Human plasma fibrin sealant, vapor-heated, solvent-detergent (Artiss), 2 ml   |
| C9734 | Focused ultrasound ablation/therapeutic intervention, other than uterine leiomyomata, with magnetic resonance (MR) guidance   |
| C9751 | Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s) |
| C9756 | Intraoperative near-infrared fluorescence lymphatic mapping of lymph node(s) (sentinel or tumor draining) with administration of indocyanine green (ICG) (List separately in addition to code for primary procedure)  |
| C9757 | Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and excision of herniated intervertebral disc, and repair of annular defect with implantation of bone anchored annular closure device, including annular defect measurement, alignment and sizing assessment, and image guidance; 1 interspace, lumbar   |
| C9758 | Blinded procedure for NYHA Class III/IV heart failure; transcatheter implantation of interatrial shunt or placebo control, including right heart catheterization, transesophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study   |
| C9759 | Transcatheter intraoperative blood vessel microinfusion(s) (e.g., intraluminal, vascular wall and/or perivascular) therapy, any vessel, including radiological supervision and interpretation, when performed   |
| C9760 | Non-randomized, non-blinded procedure for nyha class ii, iii, iv heart failure; transcatheter implantation of interatrial shunt or placebo control, including right and left heart catheterization, transeptal puncture, trans-esophageal echocardiography (tee)/intracardiac echocardiography (ice), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (ide) study                         |
| C9761 | Cystourethroscopy, with ureteroscopy and/or pyeloscopy, with lithotripsy (ureteral catheterization is included) and vacuum aspiration of the kidney, collecting system and urethra if applicable  |
| C9764 | Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed  |
| C9765 | Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed   |



|       |   |
|-------|---|
| C9766 | Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s), when performed  |
| C9767 | Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel(s), when performed   |
| C9768 | Endoscopic ultrasound-guided direct measurement of hepatic portosystemic pressure gradient by any method (list separately in addition to code for primary procedure)  |
| C9769 | Cystourethroscopy, with insertion of temporary prostatic implant/stent with fixation/anchor and incisional struts   |
| C9771 | Nasal/sinus endoscopy, cryoablation nasal tissue(s) and/or nerve(s), unilateral or bilateral  |
| C9772 | Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies), with intravascular lithotripsy, includes angioplasty within the same vessel (s), when performed   |
| C9773 | Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed   |
| C9774 | Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel (s), when performed   |
| C9775 | Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel (s), when performed  |
| C9776 | Intraoperative near-infrared fluorescence imaging of major extra-hepatic bile duct(s) (e.g., cystic duct, common bile duct and common hepatic duct) with intravenous administration of indocyanine green (icg) (list separately in addition to code for primary procedure)  |
| C9777 | Esophageal mucosal integrity testing by electrical impedance, transoral (list separately in addition to code for primary procedure)   |
| C9779 | Endoscopic submucosal dissection (ESD), including endoscopy or colonoscopy, mucosal closure, when performed   |
| C9781 | Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (e.g., balloon), includes debridement (e.g., limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed  |
| C9782 | Blinded procedure for new york heart association (nyha) class ii or iii heart failure, or canadian cardiovascular society (ccs) class iii or iv chronic refractory angina; transcatheter intramyocardial transplantation of autologous bone marrow cells (e.g., mononuclear) or placebo control, autologous bone marrow harvesting and preparation for transplantation, left heart catheterization including ventriculography, all laboratory services, and all imaging with or without guidance (e.g., transthoracic echocardiography, ultrasound, |



|   |   |
|---|---|
|   | fluoroscopy), performed in an approved investigational device exemption (ide) study   |
| C9783   | Blinded procedure for transcatheter implantation of coronary sinus reduction device or placebo control, including vascular access and closure, right heart catheterization, venous and coronary sinus angiography, imaging guidance and supervision and interpretation when performed in an approved investigational device exemption (ide) study |
| C9784   | Gastric restrictive procedure, endoscopic sleeve gastropasty, with esophagogastroduodenoscopy and intraluminal tube insertion, if performed, including all system and tissue anchoring components   |
| C9785   | Endoscopic outlet reduction, gastric pouch application, with endoscopy and intraluminal tube insertion, if performed, including all system and tissue anchoring components  |
| C9786   | Echocardiography image post processing for computer aided detection of heart failure with preserved ejection fraction, including interpretation and report  |
| C9787   | Gastric electrophysiology mapping with simultaneous patient symptom profiling   |
| C9793   | 3d predictive model generation for pre-planning of a cardiac procedure, using data from cardiac computed tomographic angiography with report  |
| C9796   | Repair of enterocutaneous fistula small intestine or colon (excluding anorectal fistula) with plug (e.g., porcine small intestine submucosa [sis])  |
| C9797   | Vascular embolization or occlusion procedure with use of a pressure-generating catheter (e.g., one-way valve, intermittently occluding), inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction        |
| C9901   | Endoscopic defect closure within the entire gastrointestinal tract, including upper endoscopy (including diagnostic, if performed) or colonoscopy (including diagnostic, if performed), with all system and tissue anchoring components   |
| CARTIVA® SCI Synthetic Cartilage Implant for Joint Pain | CARTIVA® SCI Synthetic Cartilage Implant for Joint Pain   |
| Cefaly Device   | Cefaly is a small, portable, battery-powered, prescription device that resembles a plastic headband worn across the forehead and atop the ears as a treatment for migraines   |
| Central Auditory Processing Disorder Hearing Exam       | Central Auditory Processing Disorder Hearing Exam   |
| Cold and Compression Therapy Devices                    | brand names:Game Ready, NICE 1  |
| Cold Caps and Cold Cap Systems                          | Cold Caps including but not limited to DigniCap, Arctic, Paxman Scalp, Polar, Penguin, Chemo, ElastoGels, and Moleskin Plus brands”   |
| Coolief Radiofrequency Device and Treatment             | Coolief Radiofrequency Device and Treatment   |



|                                    |  |
|------------------------------------|--|
| Corus CAD Gene Expression test     | Corus Coronary Artery Disease Gene Expression test   |
| Cranial electrotherapy stimulation | Cranial electrotherapy stimulation (CES), also known as cranial electrical stimulation, transcranial electrical stimulation, or electrical stimulation therapy for the treatment of anxiety and migraines using a device called Alpha-Stim   |
| Craniosacral therapy               | Craniosacral Therapy also referred to as cranial osteopathy, cranial therapy, bio-cranial therapy, bio cranial stretching, Craniopathy, Sacro Occipital technique, involves intrinsic movements of the bones of the skull which are believed to reveal different rhythmic tidal motions in the body. |
| Dry Needling                       | Dry Needling   |
| E0183                              | Powered pressure reducing underlay/pad, alternating, with pump, includes heavy duty  |
| E0446                              | Topical oxygen delivery system, not otherwise specified, includes all supplies and accessories   |
| E0490                              | Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by hardware remote   |
| E0491                              | Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by hardware remote, 90-day supply  |
| E0492                              | Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by phone application   |
| E0493                              | Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply  |
| E0530                              | Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type  |
| E0677                              | Non-pneumatic sequential compression garment, trunk  |
| E0678                              | Non-pneumatic sequential compression garment, full leg   |
| E0679                              | Non-pneumatic sequential compression garment, half leg   |
| E0680                              | Non-pneumatic compression controller with sequential calibrated gradient pressure  |
| E0681                              | Non-pneumatic compression controller without calibrated gradient pressure  |
| E0682                              | Non-pneumatic sequential compression garment, full arm   |
| E0732                              | Cranial electrotherapy stimulation (ces) system, any type  |
| E0733                              | Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve  |
| E0734                              | External upper limb tremor stimulator of the peripheral nerves of the wrist  |
| E0735                              | Non-invasive vagus nerve stimulator  |
| E0736                              | Transcutaneous tibial nerve stimulator   |
| E0738                              | Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, include microprocessor, all components and accessories  |





|   |   |
|---|---|
| E0740   | Nonimplanted pelvic floor electrical stimulator, complete system  |
| E0743   | External lower extremity nerve stimulator for restless legs syndrome, each  |
| E0770   | Functional Electrical Stimulation Device  |
| E1629   | Tablo hemodialysis system for the billable dialysis service   |
| E1905   | Virtual reality cognitive behavioral therapy device (cbt), including pre-programmed therapy software  |
| E2104   | Home blood glucose monitor for use with integrated lancing/blood sample testing cartridge   |
| E3000   | Speech volume modulation system, any type, including all components and accessories   |
| Embrace 2 seizure monitoring smart wristband                | Embrace 2 seizure monitoring smart wristband  |
| Emsella Treatment   | Emsella is a breakthrough treatment for incontinence and confidence. Emsella utilizes High-Intensity Focused Electromagnetic (HIFEM) technology to stimulate deep pelvic floor muscles and restore neuromuscular control.   |
| EndeavorRx  | EndeavorRx app is a digital treatment indicated for Children with ADHD  |
| Epilepsy Watch  | Epilepsy Watch - called Embrace   |
| Fisher Wallace stimulator                                   | Fisher Wallace stimulator   |
| FlexiGraft  | FlexiGraft  |
| Freespira Digital Therapeutic for Panic Disorder and PTSD   | Freespira Digital Therapeutic for Panic Disorder and PTSD   |
| G0176   | Activity therapy, such as music, dance, art or play therapies not for recreation, related to the care and treatment of patient's disabling mental health problems, per session (45 minutes or more)                         |
| G0465   | Autologous platelet rich plasma (prp) for diabetic chronic wounds/ulcers, using an fda-cleared device (includes administration, dressings, phlebotomy, centrifugation, and all other preparatory procedures, per treatment) |
| Gammacore Non-Invasive Vagus Nerve Stimulator for headaches | Gammacore Non-Invasive Vagus Nerve Stimulator for headaches   |
| Genecept Assay  | Genecept Assay  |
| GeneSight Testing   | There is interest in the use of genetic testing to help in medication selection for psychiatric conditions  |
| GI MAP Testing/IgG MAP Food Sensitivity Testing             | GI MAP Testing/IgG MAP Food Sensitivity Testing   |
| Hair Follicle Toxic Element Exposure Profile test           | A Metals Hair Test is ideal for checking current exposure to toxic metals   |
| heel ultrasound as a bone density screening                 | heel ultrasound as a bone density screening   |
| High Energy Shock Wave Therapy                              | ESWT for foot conditions is not covered   |



|   |  |
|---|--|
| Homeopathic Sports Therapy              | Homeopathic sports therapy   |
| Implantable hormone pellets             | Implantable hormone pellets for the treatment of menopausal symptoms (PRE MENOPAUSE)   |
| Integrative Medicine Consults           | Integrative Medicine Consults  |
| Intense Pulse Light for Dry Eye Disease | Intense Pulse Light for Dry Eye Disease  |
| lovera System                           | Cryoneurolysis using the Lovera System (CPT Code 64640 is not an appropriate code for Lovera system)   |
| J0591                                   | Injection, deoxycholic acid, 1 mg  |
| J3570                                   | Laetrile   |
| J7168                                   | Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activity   |
| J7677                                   | Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through DME, 1 microgram   |
| K1001                                   | Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type  |
| K1002                                   | Cranial electrotherapy stimulation (CES) system, includes all supplies and accessories, any type   |
| K1004                                   | Low frequency ultrasonic diathermy treatment device for home use, includes all components and accessories  |
| K1007                                   | Bilateral hip, knee, ankle, foot device, powered, includes pelvic component, single or double upright(s), knee joints any type, with or without ankle joints any type, includes all components and accessories, motors, microprocessors, sensors |
| K1009                                   | Speech volume modulation system, any type, including all components and accessories  |
| K1014                                   | Addition, endoskeletal knee-shin system, 4 bar linkage or multiaxial, fluid swing and stance phase control   |
| K1016                                   | Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve  |
| K1017                                   | Monthly supplies for use of device coded at k1016  |
| K1018                                   | External upper limb tremor stimulator of the peripheral nerves of the wrist  |
| K1019                                   | Monthly supplies for use of device coded at k1018  |
| K1020                                   | Non-invasive vagus nerve stimulator  |
| K1021                                   | Exsufflation belt, includes all supplies and accessories   |
| K1022                                   | Addition to lower extremity prosthesis, endoskeletal, knee disarticulation, above knee, hip disarticulation, positional rotation unit, any type  |
| K1023                                   | Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm. Nerivio Migra Device   |
| K1024                                   | Nonpneumatic compression controller with sequential calibrated gradient pressure   |
| K1025                                   | Nonpneumatic sequential compression garment, full arm  |



|   |  |
|---|--|
| K1027   | Oral device/appliance used to reduce upper airway collapsibility, without fixed mechanical hinge, custom fabricated, includes fitting and adjustment   |
| K1028   | Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle for the reduction of snoring and obstructive sleep apnea, controlled by phone application  |
| K1029   | Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply  |
| K1030   | External recharging system for battery (internal) for use with implanted cardiac contractility modulation generator, replacement only  |
| K1031   | Non-pneumatic compression controller without calibrated gradient pressure  |
| K1032   | Non-pneumatic sequential compression garment, full leg   |
| K1033   | Non-pneumatic sequential compression garment, half leg   |
| K1036   | Supplies and accessories (e.g., transducer) for low frequency ultrasonic diathermy treatment device, per month   |
| L2006   | Knee-ankle-foot (KAF) device, any material, single or double upright, swing and/or stance phase microprocessor control with adjustability, includes all components (e.g., sensors, batteries, charger), any type activation, with or without ankle joint(s), custom fabricated |
| L3674   | Shoulder orthotic, abduction positioning (airplane design), thoracic component and support bar, with or without nontorsion joint/turnbuckle, may include soft interface, straps, custom fabricated, includes fitting and adjustment  |
| L5991   | Addition to lower extremity prostheses, osseointegrated external prosthetic connector  |
| L8605   | Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, anal canal, 1 ml, includes shipping and necessary supplies  |
| L8608   | Miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system  |
| L8678   | Electrical stimulator supplies (external) for use with implantable neurostimulator, per month  |
| L8701   | Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated  |
| L8702   | Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated  |
| L8720   | External lower extremity sensory prosthesis, cutaneous stimulation of mechanoreceptors proximal to the ankle, per leg  |
| Laser treatment experimental and investigational for removal nail fungus (Onychomycosis). | Laser treatment experimental and investigational for removal nail fungus (Onychomycosis).  |



|   |  |
|---|--|
| Laser treatment for Lichen sclerosis                        | Laser treatment for Lichen sclerosis   |
| Laser treatment to rosacea with an IPL beam or Excel V beam | Laser treatment to rosacea with an IPL beam or Excel V beam  |
| Latera Absorbable Nasal Implant                             | Latera Absorbable Nasal Implant  |
| Lidocaine Infusion-for pain management                      | Lidocaine Infusion-for pain management   |
| Linx Reflux Management System                               | The LINX Reflux Management System. Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device  |
| M0076   | Prolotherapy   |
| M0240   | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring, subsequent repeat doses  |
| M0241   | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses |
| M0243   | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring   |
| M0244   | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency                          |
| M0245   | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring  |
| M0246   | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency   |
| Massage Therapy   | Massage Therapy performed by a massage therapist.  |
| Medtronic Extended Insulin Infusion Set                     | Medtronic Extended Insulin Infusion Set  |
| miraDry for reduce underarm sweat                           | miraDry for reduce underarm sweat  |
| Monalisa Touch  | Monalisa Touch   |
| MySentry by MedTronics.                                     | Remote Glucose Monitoring for patients with type 1 diabetes (including pregnant women with poorly controlled type 1 diabetes)  |
| Nail Fungus Laser Surgery                                   | Treatment of nail fungus with laser  |
| NeuroMD Corrective Therapy Device                           | NeuroMD Corrective Therapy Device  |



|   |  |
|---|--|
| Oasis Pro Cranio-Electro Stimulatio Device        | Oasis Pro CES Device- Cranio-Electro Stimulation   |
| Ozone Therapy or Oxidative Therapy                | Ozone Therapy/Oxidative Therapy  |
| Pantaloons  | Pantaloons   |
| Per Oral Endoscopic Myotomy                       | Per Oral Endoscopic Myotomy (POEM)   |
| Proton Beam Radiation Therapy for Prostate Cancer | Proton Beam Radiation Therapy for Prostate Cancer  |
| Pulsed RF ablation                                | Radiofrequency (RF) treatment is a minimally invasive procedure that has been used for treating various chronic pain syndromes |
| Q0240   | Injection, casirivimab and imdevimab, 600 mg   |
| Q0243   | Injection, casirivimab and imdevimab, 2400 mg  |
| Q0244   | Injection, casirivimab and imdevimab, 1200 mg  |
| Q0245   | Injection, bamlanivimab and etesevimab, 2100 mg  |
| Q4155   | Neox Flo or Clarix Flo 1 mg  |
| Q4156   | Neox 100 or Clarix 100, per sq cm  |
| Q4157   | Revitalon, per sq cm   |
| Q4158   | Kerecis Omega3, per sq cm  |
| Q4159   | Affinity, per square centimeter  |
| Q4160   | Nushield, per square centimeter  |
| Q4161   | Bio-ConneKt wound matrix, per sq cm  |
| Q4166   | Cytal, per sq cm   |
| Q4167   | Truskin, per sq cm   |
| Q4168   | AmnioBand, 1 mg  |
| Q4169   | Artacent wound, per sq cm  |
| Q4170   | Cygnus, per sq cm  |
| Q4171   | Interfyl, 1 mg   |
| Q4173   | PalinGen or PalinGen XPlus, per sq cm  |
| Q4174   | PalinGen or ProMatrX, 0.36 mg per 0.25 cc  |
| Q4175   | Miroderm, per sq cm  |
| Q4176   | Neopatch, per square centimeter  |
| Q4177   | Floweramnioflo, 0.1 cc   |
| Q4178   | Floweramniopatch, per square centimeter  |
| Q4179   | Flowerderm, per square centimeter  |
| Q4180   | Revita, per square centimeter  |
| Q4181   | Amnio wound, per square centimeter   |
| Q4182   | Transcyte, per square centimeter   |
| Q4183   | Surgigraft, per square centimeter  |



|       |   |
|-------|---|
| Q4184 | Cellesta, per square centimeter   |
| Q4185 | Cellesta flowable amnion (25 mg per cc); per 0.5 cc   |
| Q4187 | Epicord, per square centimeter  |
| Q4188 | Amnioarmor, per square centimeter   |
| Q4189 | Artacent ac, 1 mg   |
| Q4190 | Artacent ac, per square centimeter  |
| Q4191 | Restorigin, per square centimeter   |
| Q4192 | Restorigin, 1 cc  |
| Q4193 | Coll-e-derm, per square centimeter  |
| Q4194 | Novachor, per square centimeter   |
| Q4195 | Puraply, per square centimeter  |
| Q4196 | Puraply am, per square centimeter   |
| Q4197 | Puraply xt, per square centimeter   |
| Q4198 | Genesis amniotic membrane, per square centimeter  |
| Q4199 | Cygnus matrix, per square centimeter  |
| Q4200 | Skin te, per square centimeter  |
| Q4201 | Matrion, per square centimeter  |
| Q4202 | Keroxx (2.5g/cc), 1cc   |
| Q4203 | Derma-gide, per square centimeter   |
| Q4204 | Xwrap, per square centimeter  |
| Q4205 | Membrane graft or membrane wrap, per square centimeter  |
| Q4206 | Fluid flow or fluid GF, 1 cc  |
| Q4208 | Novafix, per square centimeter  |
| Q4209 | Surgraft, per square centimeter   |
| Q4210 | Axolotl graft or axolotl dualgraft, per square centimeter   |
| Q4211 | Amnion bio or Axobiomembrane, per square centimeter   |
| Q4212 | Allogen, per cc   |
| Q4213 | Ascent, 0.5 mg  |
| Q4214 | Cellesta cord, per square centimeter  |
| Q4215 | Axolotl ambient or axolotl cryo, 0.1 mg   |
| Q4216 | Artacent cord, per square centimeter  |
| Q4217 | Woundfix, BioWound, Woundfix Plus, BioWound Plus, Woundfix Xplus or BioWound Xplus, per square centimeter |
| Q4218 | Surgicord, per square centimeter  |
| Q4219 | Surgigraft-dual, per square centimeter  |
| Q4220 | BellaCell HD or Surederm, per square centimeter   |
| Q4221 | Amniowrap2, per square centimeter   |
| Q4222 | Progenamatrix, per square centimeter  |
| Q4224 | Human health factor 10 amniotic patch (hhf10-p), per square centimeter                                    |



|       |   |
|-------|---|
| Q4225 | Amniobind, per square centimeter  |
| Q4226 | MyOwn skin, includes harvesting and preparation procedures, per square centimeter |
| Q4227 | Amniocore, per square centimeter  |
| Q4229 | Cogenex amniotic membrane, per square centimeter                                  |
| Q4230 | Cogenex flowable amnion, per 0.5 cc   |
| Q4231 | Corplex p, per cc   |
| Q4232 | Corplex, per square centimeter  |
| Q4233 | Surfactor or nudyn, per 0.5 cc  |
| Q4234 | Xcellerate, per square centimeter   |
| Q4235 | Amniorepair or altiPLY, per square centimeter                                     |
| Q4237 | Cryo-cord, per square centimeter  |
| Q4238 | Derm-maxx, per square centimeter  |
| Q4239 | Amnio-maxx or amnio-maxx lite, per square centimeter                              |
| Q4240 | Corecyte, for topical use only, per 0.5 cc  |
| Q4241 | Polycyte, for topical use only, per 0.5 cc  |
| Q4242 | Amniocyte plus, per 0.5 cc  |
| Q4244 | Procenta, per 200 mg  |
| Q4245 | Amniotext, per cc   |
| Q4246 | Coretext or protext, per cc   |
| Q4247 | Amniotext patch, per square centimeter  |
| Q4248 | Dermacyte amniotic membrane allograft, per square centimeter                      |
| Q4249 | AmniPLY, for topical use only, per square centimeter                              |
| Q4250 | Amnioamp-mp, per square centimeter  |
| Q4251 | Vim, per sq cm  |
| Q4252 | Vendaje, per sq cm  |
| Q4253 | Zenith Amniotic Membrane, per sq cm   |
| Q4254 | Novafix dl, per square centimeter   |
| Q4255 | Reguard, for topical use only, per square centimeter                              |
| Q4256 | Mlg-complete, per square centimeter   |
| Q4257 | Relese, per square centimeter   |
| Q4258 | Enverse, per square centimeter  |
| Q4259 | Celera dual layer or celera dual membrane, per square centimeter                  |
| Q4260 | Signature apatch, per square centimeter   |
| Q4261 | Tag, per square centimeter  |
| Q4262 | Dual layer impax membrane, per square centimeter                                  |
| Q4263 | Surgraft tl, per square centimeter  |
| Q4264 | Cocoon membrane, per square centimeter  |
| Q4265 | Neostim tl, per square centimeter   |



|       |  |
|-------|--|
| Q4266 | Neostim membrane, per square centimeter                  |
| Q4267 | Neostim dl, per square centimeter                        |
| Q4268 | Surgraft ft, per square centimeter                       |
| Q4269 | Surgraft xt, per square centimeter                       |
| Q4270 | Complete sl, per square centimeter                       |
| Q4271 | Complete ft, per square centimeter                       |
| Q4272 | Esano a, per square centimeter                           |
| Q4273 | Esano aaa, per square centimeter                         |
| Q4274 | Esano ac, per square centimeter                          |
| Q4275 | Esano aca, per square centimeter                         |
| Q4276 | Orion, per square centimeter                             |
| Q4277 | Woundplus membrane or e-graft, per square centimeter     |
| Q4278 | Epieffect, per square centimeter                         |
| Q4279 | Vendaje ac, per square centimeter                        |
| Q4280 | Xcell amnio matrix, per square centimeter                |
| Q4281 | Barrera sl or barrera dl, per square centimeter          |
| Q4282 | Cygnus dual, per square centimeter                       |
| Q4283 | Biovance tri-layer or biovance 3l, per square centimeter |
| Q4284 | Dermabind sl, per square centimeter                      |
| Q4285 | Nudyn dl or nudyn dl mesh, per square centimeter         |
| Q4286 | Nudyn sl or nudyn slw, per square centimeter             |
| Q4287 | Dermabind dl, per square centimeter                      |
| Q4288 | Dermabind ch, per square centimeter                      |
| Q4289 | Revoshield + amniotic barrier, per square centimeter     |
| Q4290 | Membrane wrap-hydro, per square centimeter               |
| Q4291 | Lamellas xt, per square centimeter                       |
| Q4292 | Lamellas, per square centimeter                          |
| Q4293 | Acesso dl, per square centimeter                         |
| Q4294 | Amnio quad-core, per square centimeter                   |
| Q4295 | Amnio tri-core amniotic, per square centimeter           |
| Q4296 | Rebound matrix, per square centimeter                    |
| Q4297 | Emerge matrix, per square centimeter                     |
| Q4298 | Amnicore pro, per square centimeter                      |
| Q4299 | Amnicore pro+, per square centimeter                     |
| Q4300 | Acesso tl, per square centimeter                         |
| Q4301 | Activate matrix, per square centimeter                   |
| Q4302 | Complete aca, per square centimeter                      |
| Q4303 | Complete aa, per square centimeter                       |
| Q4304 | Grafix plus, per square centimeter                       |





|       |  |
|-------|--|
| Q4305 | American amnion ac tri-layer, per square centimeter                    |
| Q4306 | American amnion ac, per square centimeter                              |
| Q4307 | American amnion, per square centimeter                                 |
| Q4308 | Sanopellis, per square centimeter                                      |
| Q4309 | Via matrix, per square centimeter                                      |
| Q4310 | Procenta, per 100 mg   |
| Q4311 | Acesso, per square centimeter  |
| Q4312 | Acesso ac, per square centimeter                                       |
| Q4313 | Dermabind fm, per square centimeter                                    |
| Q4314 | Reeva ft, per square centimeter  |
| Q4315 | Regenelink amniotic membrane allograft, per square centimeter          |
| Q4316 | Amchoplast, per square centimeter                                      |
| Q4317 | Vitograft, per square centimeter                                       |
| Q4318 | E-graft, per square centimeter   |
| Q4319 | Sanograft, per square centimeter                                       |
| Q4320 | Pellograft, per square centimeter                                      |
| Q4321 | Renograft, per square centimeter                                       |
| Q4322 | Caregraft, per square centimeter                                       |
| Q4323 | Alloply, per square centimeter   |
| Q4324 | Amniotx, per square centimeter   |
| Q4325 | Acapatch, per square centimeter  |
| Q4326 | Woundplus, per square centimeter                                       |
| Q4327 | Duoamnion, per square centimeter                                       |
| Q4328 | Most, per square centimeter  |
| Q4329 | Singlay, per square centimeter   |
| Q4330 | Total, per square centimeter   |
| Q4331 | Axolotl graft, per square centimeter                                   |
| Q4332 | Axolotl dualgraft, per square centimeter                               |
| Q4333 | Ardeograft, per square centimeter                                      |
| Q4334 | Amnioplast 1, per square centimeter                                    |
| Q4335 | Amnioplast 2, per square centimeter                                    |
| Q4336 | Artacent c, per square centimeter                                      |
| Q4337 | Artacent trident, per square centimeter                                |
| Q4338 | Artacent velos, per square centimeter                                  |
| Q4339 | Artacent vericlen, per square centimeter                               |
| Q4340 | Simpligraft, per square centimeter                                     |
| Q4341 | Simplimax, per square centimeter                                       |
| Q4342 | Theramend, per square centimeter                                       |
| Q4343 | Dermacyte ac matrix amniotic membrane allograft, per square centimeter |



|   |   |
|---|---|
| Q4344   | Tri-membrane wrap, per square centimeter  |
| Q5109   | Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg  |
| Q9982   | Flutemetamol F18, diagnostic, per study dose, up to 5 millicuries   |
| Q9983   | Florbetaben F18, diagnostic, per study dose, up to 8.1 millicuries  |
| Reflexology                                       | Reflexology is the application of pressure to areas on the feet or the hands  |
| Reiki   | Reiki   |
| Robotic laser treatment for Covid 19 long haulers | Robotic laser treatment for Covid 19 long haulers   |
| ROMTech PortableConnect Device                    | ROMTech PortableConnect Device  |
| S1091   | Stent, non-coronary, temporary, with delivery system (propel)   |
| S2300   | Arthroscopy, shoulder, surgical; with thermally-induced capsulorrhaphy  |
| S3722   | Dose optimization by area under the curve (AUC) analysis, for infusional 5-fluorouracil   |
| S8080   | Scintimammography (radioimmunosintigraphy of the breast), unilateral, including supply of radiopharmaceutical   |
| S8130   | Interferential current stimulator, 2 channel  |
| S8131   | Interferential current stimulator, 4 channel  |
| S8948   | Application of a modality (requiring constant provider attendance) to one or more areas; low-level laser; each 15 minutes;<br>Low Level laser Therapy (aka Red-Light Therapy) related to Skin;<br>Cold laser Therapy, Low Level Light Therapy, Photobiomodulation |
| S9034   | Extracorporeal shockwave lithotripsy for gall stones  |
| S9090   | Vertebral axial decompression, per session  |
| S9432   | Medical foods for noninborn errors of metabolism  |
| Saunders Lumbar home Traction Devices             | Saunders Lumbar home Traction Devices   |
| Schroth method of Physical Therapy                | Schroth method of Physical Therapy  |
| Shock Wave Therapy                                | ESWT for foot conditions is not covered   |
| Speech Therapy tool' Speech Buddies               | Speech Buddies Tools can help anyone over four years old that has problems with one or more of the R, S, L, SH, or CH sounds.   |
| Stem Cell Therapy                                 | Stem Cell therapy for the treatment of osteoarthritis   |
| Suit therapy/Dynamic Movement Orthosis (DMO)      | Suit therapy/Dynamic Movement Orthosis (DMO)  |
| Symfony Toric vision intraocular lenses           | Symfony Toric vision intraocular lenses   |
| The Dutch hormone Test                            | The Dutch hormone Test  |
| Thermal Shrinkage                                 | Also referred to as Electrothermal Shrinkage or Thermal Capsulorrhaphy  |
| Trexo Robotics home gait trainer                  | electro-mechanical gait assist for Rifton gait trainer  |



|   |  |
|---|--|
| Upper Limb Myoelectric Orthosis                             | Upper Limb Myoelectric Orthosis  |
| Vestibular Evoked Myogenic Potential Testing (VEMP) or VsEP | The oVEMP test differs from another vestibular-evoked myogenic potential recorded by surface EMG electrodes over the sternocleidomastoid muscles in that the cervical vestibular-evoked myogenic potential (cVEMP) due to saccular activation is measured. |
| Vibroacoustic Therapy System                                | Vibroacoustic Therapy System   |
| Virtual Reality Therapy                                     | Virtual Reality Therapy  |
| Vivaer Procedure  | Vivaer radiofrequency ablation for treatment of nasal obstruction  |
| Whole Body Hyperthermia treatment for Lyme Disease          | Whole Body Hyperthermia treatment for Lyme Disease   |
| Wilderness Therapy  | Wilderness Therapy   |

**Effective**

February 2025: Ad hoc update. Codes updated.

December 2024: Ad hoc update. Codes updated. Medicare Advantage language clarified. MassHealth language added. References updated.

August 2024: Ad hoc update. Codes updated.

May 2024: Annual update. Medicare Advantage language added. Codes updated.

September 2023: Ad hoc update. Medtronic Extended Infusion Set removed from policy.

August 2023: Ad hoc update. Codes updated.

July 2023: Ad hoc update. Codes updated.

May 2023: Annual update.

January 2023: Ad hoc update. Codes updated.

October 2022: Ad hoc update. Codes updated.

July 2022: Ad hoc update. Codes updated.

May 2022: Annual update. Under Coverage Guidelines, added verbiage “high-quality” to case control studies. Codes updated.

March 2022: Ad hoc update. Codes updated.

January 2022: Ad hoc update. Codes updated.

October 2021: Ad hoc update. Codes updated.

September 2021: Ad hoc update. Codes updated.

August 2021: Ad hoc update. Codes updated.

July 2021: Annual update. Codes updated.

April 2021: Ad hoc update. Codes updated.

March 2021: Ad hoc update. Codes updated.

February 2021: Ad hoc update. Codes updated.

September 2020: Ad hoc update. Codes updated.

August 2020: Ad hoc update. Codes updated.

July 2020: Ad hoc update. Codes updated.

May 2020: Annual update.

March 1, 2020: Ad hoc update. Codes updated.

October 1, 2019: Ad hoc update. Codes updated.



August 2019: Annual update. Codes updated.  
May 2019: Ad hoc update. Code update.  
December 2018: Annual update.  
October 2018: Ad hoc update. Added additional codes.  
April 2018: Annual update. Added codes.  
April 2017: Annual update. Added language to include General laws.  
February 2017: Annual update.  
February 2016: Annual update.  
February 2015: Effective date.

## **References**

Accountable Care Partnership Plan Contract for the MassHealth Accountable Care Organization Program, Appendix C, Exhibit 4: MassHealth Excluded Services – All Coverage Types

General Laws of Massachusetts Chapter 175: Section 47K. Off-label drug use; cancer treatment

General Laws of Massachusetts Chapter 175: Section 47O. HIV/AIDS treatment; insurance coverage for certain off-label use of prescription drugs

General Laws of Massachusetts Chapter 176G: Section 4F. Group health maintenance contracts; coverage for bone marrow transplants

General Laws of Massachusetts Chapter 176G: Section 4G. Off-label use of prescription drugs for HIV/AIDS treatment

General Laws of Massachusetts - Part I, Title XXII, Chapter 175, Section 110L–Clinical Trials; Definition

Public Law 111 - 148 - Patient Protection and Affordable Care Act, Section 2709

Division of Insurance Bulletin 2002-13 Re: Insurance Coverage of Qualified Clinical Trials

